



**Commonwealth Pennsylvania  
Department of Human Services  
Children’s Health Insurance Program**

**2019 External Quality Review Report  
UPMC for Kids**

Final Report  
August 2020



Better healthcare,  
realized.

Corporate Headquarters  
1979 Marcus Avenue  
Lake Success, NY 11042-1072  
(516) 326-7767  
ipro.org

ISO  
9001:2008  
CERTIFIED

# Table of Contents

<b>INTRODUCTION</b> .....	<b>4</b>
PURPOSE AND BACKGROUND .....	4
<b>I: STRUCTURE AND OPERATIONS STANDARDS</b> .....	<b>5</b>
METHODOLOGY AND FORMAT .....	5
DETERMINATION OF COMPLIANCE .....	6
SUBPART C: ENROLLEE RIGHTS AND PROTECTIONS .....	6
SUBPART D: QUALITY ASSESSMENT AND PERFORMANCE IMPROVEMENT REGULATIONS .....	7
SUBPART H: CERTIFICATIONS AND PROGRAM INTEGRITY .....	8
<b>II. PERFORMANCE IMPROVEMENT PROJECTS</b> .....	<b>10</b>
VALIDATION METHODOLOGY .....	11
REVIEW ELEMENT DESIGNATION/WEIGHTING .....	11
SCORING MATRIX .....	12
FINDINGS .....	12
<b>III. PERFORMANCE MEASURES AND CAHPS® SURVEY</b> .....	<b>15</b>
METHODOLOGY .....	15
PENNSYLVANIA (PA)-SPECIFIC PERFORMANCE MEASURE SELECTION AND DESCRIPTIONS .....	18
<i>PA Specific Administrative Measures</i> .....	18
HEDIS® PERFORMANCE MEASURE SELECTION AND DESCRIPTIONS .....	19
<i>Implementation of PA-Specific Performance Measures and HEDIS® Audit</i> .....	22
FINDINGS .....	23
<i>Access to/Availability of Care</i> .....	23
<i>Well-Care Visits and Immunizations</i> .....	24
<i>EPSDT/Bright Futures: Screenings and Follow-up</i> .....	26
<i>Dental Care for Children</i> .....	26
<i>Respiratory Conditions</i> .....	27
<i>Behavioral Health</i> .....	28
<i>Utilization</i> .....	28
CONSUMER ASSESSMENT OF HEALTHCARE PROVIDERS AND SYSTEMS (CAHPS®) SURVEY .....	32
<i>Satisfaction with the Experience of Care</i> .....	32
<i>2019 Child CAHPS® 5.0H Survey Results</i> .....	32
<b>IV: 2018 OPPORTUNITIES FOR IMPROVEMENT MCO RESPONSE</b> .....	<b>33</b>
CURRENT AND PROPOSED INTERVENTIONS .....	33
<b>V. 2019 STRENGTHS AND OPPORTUNITIES FOR IMPROVEMENT</b> .....	<b>40</b>
STRENGTHS .....	40
OPPORTUNITIES FOR IMPROVEMENT .....	40
<b>VI. SUMMARY OF ACTIVITIES</b> .....	<b>41</b>
STRUCTURE AND OPERATIONS STANDARDS .....	41
PERFORMANCE IMPROVEMENT PROJECTS .....	41
PERFORMANCE MEASURES .....	41
2018 OPPORTUNITIES FOR IMPROVEMENT MCO RESPONSE .....	41
2019 STRENGTHS AND OPPORTUNITIES FOR IMPROVEMENT .....	41
<b>APPENDIX</b> .....	<b>42</b>

## List of Tables and Figures

Table 1.1: Compliance Items and Subcategories .....	5
Table 1.2: MCO Compliance with Subpart C: Enrollee Rights and Protections Regulations .....	7
Table 1.3: MCO Compliance with Subpart D: Quality Assessment and Performance Improvement Regulations .....	7
Table 1.4: MCO Compliance with Subpart H: Certifications and Program Integrity.....	8
Table 2.2: UPMC PIP Compliance Assessments – Interim Reports .....	14
Table 3.1: Performance Measure Groupings .....	15
Table 3.2: Access to Care .....	24
Table 3.3: Well-Care Visits and Immunizations .....	24
Table 3.4: EPSDT/Bright Futures: Screenings and Follow-up.....	26
Table 3.5: Dental Care for Children.....	27
Table 3.6: Respiratory Conditions .....	27
Table 3.7: Behavioral Health .....	28
Table 3.8: Utilization .....	29
Table 3.9: CAHPS® 2019 Child Survey Results .....	32
Table 4.1: Current and Proposed Interventions .....	33
Figure 1: Access to Care .....	42
Figure 2: Well Care I .....	42
Figure 3: Well Care II .....	43
Figure 4: Well Care III .....	43
Figure 5: Well Care IV .....	44
Figure 6: EPSDT/Bright Futures I .....	44
Figure 7: EPSDT/Bright Futures II .....	45
Figure 8: Dental Care for Children I .....	45
Figure 9: Dental Care for Children II .....	46
Figure 10: Respiratory Conditions.....	46
Figure 11: Behavioral Health.....	47
Figure 12: Utilization .....	47

## Introduction

### Purpose and Background

The final rule of the Balanced Budget Act (BBA) of 1997 requires that State agencies contract with an External Quality Review Organization (EQRO) to conduct an annual external quality review (EQR) of the services provided by contracted CHIP Managed Care Organizations (MCOs). This EQR must include an analysis and evaluation of aggregated information on quality, timeliness and access to the health care services that a MCO furnishes to CHIP Managed Care recipients.

The EQR-related activities that must be included in detailed technical reports are as follows:

- review to determine MCO compliance with structure and operations standards established by the State (42 CFR §438.358)
- validation of performance improvement projects
- validation of MCO performance measures.

The Pennsylvania (PA) Department of Human Services (DHS) Children's Health Insurance Program (CHIP) provides free or low-cost health insurance to uninsured children and teens that are not eligible for or enrolled in Medical Assistance (MA). PA CHIP has contracted with Island Peer Review Organization (IPRO) as its EQRO to conduct the 2019 EQRs for the CHIP MCOs and to prepare the technical reports. This is the second year of separate PA CHIP technical reports. The report includes six core sections:

- I. Structure and Operations Standards
- II. Performance Improvement Projects
- III. Performance Measures and Consumer Assessment of Healthcare Providers and Systems (CAHPS) Survey
- IV. 2018 Opportunities for Improvement – MCO Response
- V. 2019 Strengths and Opportunities for Improvement
- VI. Summary of Activities

For the CHIP MCOs, the information for the compliance with Structure and Operations Standards section of the report is derived from the results of on site reviews conducted by PA CHIP staff, with findings entered into the department's on site monitoring tool, and follow up materials provided as needed or requested. Standards presented in the on site tool are those currently reviewed and utilized by PA CHIP staff to conduct reviews; these standards may be applicable to other subparts, and will be crosswalked to reflect regulations as applicable.

Information for Section II of this report is derived from activities conducted with and on behalf of DHS to research, select, and define Performance Improvement Projects (PIPs) for a new validation cycle. Information for Section I of this report is derived from IPRO's validation of each CHIP MCO's performance measure submissions. Performance measure validation as conducted by IPRO includes both Pennsylvania specific performance measures as well as Healthcare Effectiveness Data and Information Set (HEDIS<sup>®1</sup>) measures for each CHIP MCO. Within Section II, CAHPS Survey results follow the performance measures.

Section IV, 2018 Opportunities for Improvement – MCO Response, includes the MCO's responses to the 2018 EQR Technical Report's opportunities for improvement and presents the degree to which the MCO addressed each opportunity for improvement.

Section V has a summary of the MCO's strengths and opportunities for improvement for this review period as determined by IPRO. This section will highlight performance measures across HEDIS<sup>®</sup> and Pennsylvania-specific performance measures where the MCO has performed highest and lowest. Section V provides a summary of EQR activities for the CHIP MCO for this review period.

---

<sup>1</sup> HEDIS<sup>®</sup> is a registered trademark of the National Committee for Quality Assurance.

## I: Structure and Operations Standards

This section of the EQR report presents a review of the CHIP MCOs compliance with structure and operations standards. The review is based on information derived from the most recent reviews of the MCO. On site reviews are conducted by CHIP annually.

The format for this section of the report was developed to be consistent with the subparts prescribed by the BBA regulations. This document groups the regulatory requirements under subject headings that are consistent with the three subparts set out in the BBA regulations and described in the *MCO Monitoring Protocol*. Under each subpart heading are the individual regulatory categories appropriate to those headings. IPRO's findings are presented in a manner consistent with the three BBA regulations subparts as explained in the Protocol, i.e., Subpart C: Enrollee Rights and Protections; Subpart D: Quality Assessment And Performance Improvement (including access, structure and operation and measurement and improvement standards); and Subpart H: Certifications and Program Integrity. As PA CHIP continues to move forward with alignment of the EQR provisions to the CHIP population, re-assessment of the review items and crosswalks may be warranted.

### Methodology and Format

Prior to the audit which is performed on-site at the MCO, documents are provided to CHIP by the MCO, which address various areas of compliance. This includes training materials, provider manuals, MCO organization charts, policies and procedures manuals, and geo access maps. These documents are reviewed prior to the onsite audit and are used to address areas of compliance which include Quality of Care, Medical Services, Provider Adequacy, Applications and Eligibility, Customer Service, Marketing Outreach, Audits, and IT Reports. These items are used to assess the MCOs overall operational, fiscal, and programmatic activities to ensure compliance with contractual obligations. Federal and state law require that CHIP conduct monitoring and oversight of its MCOs.

Throughout the audit, these areas of compliance are discussed with the MCO and clarifying information is provided, where possible. Discussions that occur are compiled along with the reviewed documentation to provide a final determination of compliance, partial compliance, or non-compliance for each section. Table 1.1 showcases each of the items and subcategories.

IPRO reviewed the most recent elements in the areas that CHIP audits and created a crosswalk to pertinent BBA regulations. A total of 31 unique items were identified that were relevant to evaluation of CHIP-MCO compliance with the BBA regulations. These Items vary in review periodicity from annually, semi-annually, quarterly, monthly and as needed. The items from Review Year (RY) 2019 provide the information necessary for this assessment. For RY 2019, Pennsylvania is designated a Cycle 1 state for CMS Payment Error Rate Measurement (PERM). The Cycle 1 review had not been completed at the time of the onsite review. PERM results and any Corrective Action Plan will be presented to CHIP MCOs in the future.

**Table 1.1: Compliance Items and Subcategories**

Subpart C: Enrollee Rights and Protections
Medical Services
PH-95
Bright Futures
Case Management
Utilization Management
Quality Improvement Plans
Quality of Care
Provider Network and Adequacy
Provider Credentialing
Appointment Standards
Communication to Providers and Members
Provider Enrollment

Application and Eligibility
Application Timeliness and Renewal Rates
UFI Random Sample
Transfers In/ Out of Enrollment
<b>Subpart D: Quality Assessment and Performance Improvement Regulations</b>
Customer Service
CHIP Dedicated Customer Service Staff
CHIP Information
Application Input
General Website and Online Manuals
Blue and Green Sheets
Marketing and Outreach
Community Outreach
Programmatic Change Requests
<b>Subpart H: Certifications and Program Integrity</b>
Audits and Reports
ERP Logs and Resolution
Fraud and Abuse
Precluded Provider Report
HIPAA Breaches
PPS Reporting
A-133
Information Technology Files and Reports
Ad Hoc
TMSIS/Encounter Data
Provider Files
Testing

## Determination of Compliance

Information necessary for the review is provided through an on-site review that is conducted by DHS CHIP. Throughout the duration of this on-site, each area highlighted above is reviewed and a rating scale is utilized to determine compliance. The MCO can be rated either “non-compliant”, “partially compliant”, or “compliant” in each area based on the findings of the audit. Following each rating scale, a comprehensive description of identified strengths and weaknesses are provided to the MCO. If all items were Compliant, the MCO was evaluated as Compliant. If some were Compliant and some were non-Compliant, the MCO was evaluated as partially-Compliant. If all items were non-Compliant, the MCO was evaluated as non-Compliant. If no items were evaluated for a given category and no other source of information was available to determine compliance, a value of Not Determined was assigned for that category.

Subsections under parts C, D and H are based on the items that were reviewed during the most recent review year. This focuses the current year’s technical reports on results that were found during the current year for compliance review. As items are required to be reviewed during a three year time period, it is possible that an MCO has been evaluated for an item but was not reviewed this year. In these instances, an N/A is notated for the MCO in the report. There is no corresponding non-compliance penalty for an MCO in this case.

## Subpart C: Enrollee Rights and Protections

31 items were evaluated for the MCO in Review Year (RY) 2019.

The general purpose of the Subpart C regulations is to ensure that each MCO has written policies regarding enrollee rights and complies with applicable Federal and State laws that pertain to enrollee rights and that the MCO ensures that the MCO’s staff and affiliated providers take into account those rights when furnishing services to enrollees. [42 C.F.R. § 438.100 (a), (b)]

**Table 1.2: MCO Compliance with Subpart C: Enrollee Rights and Protections Regulations**

<b>Subpart C: Categories</b>	<b>Compliance</b>	<b>Comments</b>
PH-95	Compliant	
Bright Futures	Compliant	
Case Management	Compliant	
Utilization Management	Compliant	
Quality Improvement Plans	Compliant	Although compliant, the plan is currently working on a CHIP newsletter article that focuses on Developmental screenings and new CHIP Facebook page.
Provider Network and Adequacy	Compliant	
Provider Credentialing	Compliant	
Appointment Standards	Compliant	
Communication to Providers and Members	Compliant	
Provider Enrollment	Compliant	
Application Timeliness and Renewal Rates	Compliant	
UFI Random Sample	Compliant	
Transfers In/ Out of Enrollment	N/A	

**Subpart D: Quality Assessment and Performance Improvement Regulations**

The general purpose of the regulations included under this heading is to ensure that all services covered under the DHS's CHIP program are available and accessible to CHIP enrollees. [42 C.F.R. § 438.206 (a)]

**Table 1.3: MCO Compliance with Subpart D: Quality Assessment and Performance Improvement Regulations**

<b>Subpart D: Categories</b>	<b>Compliance</b>	<b>Comments</b>
CHIP Dedicated Customer Service Staff	Compliant	
CHIP Information	N/A	

Subpart D: Categories	Compliance	Comments
Application Input	N/A	
General Website and Online Manuals	Compliant	
Blue and Green Sheets	Compliant	
Community Outreach	N/A	
Programmatic Change Requests	Compliant	

### Subpart H: Certifications and Program Integrity

The general purpose of the Subpart H regulations is to ensure the promotion of program integrity through programs which prevent fraud and abuse through means of misspent program funds and to promote quality health care services for CHIP enrollees. These safeguards require that the CHIP MCO make a commitment to a formal and effective fraud and abuse program. [42 C.F.R. § 438.600 (a)]

**Table 1.4: MCO Compliance with Subpart H: Certifications and Program Integrity**

Subpart H: Categories	Compliance	Comments
ERP Logs and Resolution	Compliant	
Fraud and Abuse	Compliant	
Precluded Provider Report	Compliant	
HIPAA Breaches	Compliant	
PPS Reporting	Compliant	
A-133	Compliant	
Ad Hoc	Compliant	
TMSIS/Encounter Data	Compliant	Although compliant, UPMC for Kids (UPMC) is responsible for the 2nd highest number of Missing NPI's (National Provider Identifier) in Office of CHIP claims. However, UPMC is responsible for low numbers of errors in most other categories.



Subpart H: Categories	Compliance	Comments
Provider Files	Compliant	UPMC's area they could most improve on is Group Affiliation Name. The MCO has shown that they are working on their outstanding issues and are therefore compliant.
Testing	Compliant	

## II. Performance Improvement Projects

In accordance with current BBA regulations, IPRO undertook validation of Performance Improvement Projects (PIPs) for each CHIP MCO. For the purposes of the EQR, CHIP MCOs were required to participate in studies selected by DHS CHIP for validation by IPRO in 2019 for 2018 activities. Under the applicable Agreement with the DHS in effect during this review period, CHIP MCOs are required to conduct focused studies each year. For all CHIP MCOs, two PIPs were implemented as part of this requirement. CHIP MCOs are required to implement improvement actions and to conduct follow-up in order to demonstrate initial and sustained improvement or the need for further action for each proposal.

As part of the EQR PIP cycle that was initiated for all CHIP MCOs in 2017, IPRO adopted the LEAN methodology, following the CMS recommendation that Quality Improvement Organizations (QIOs) and other healthcare stakeholders embrace LEAN in order to promote continuous quality improvement in healthcare.

2019 is the eleventh year to include validation of PIPs. For each PIP, all CHIP MCOs share the same baseline period and timeline defined for that PIP. To introduce each PIP cycle, DHS CHIP provided specific guidelines that addressed the PIP submission schedule, the measurement period, documentation requirements, topic selection, study indicators, study design, baseline measurement, interventions, re-measurement, and sustained improvement. Direction was given with regard to expectations for PIP relevance, quality, completeness, resubmissions and timeliness.

In 2018, CHIP MCOs were required to implement two internal PIPs in priority topic areas chosen by DHS. For this PIP cycle, the two topics selected were “Improving Developmental Screening Rate in Children Ages 1, 2, and 3 Years” and “Improving Blood Lead Screening Rate in Children 2 Years of Age”. Interim results included in the following section were provided by plans for both of these PIPs in 2019.

**“Improving Developmental Screening Rate in Children Ages 1, 2, and 3 Years”** was selected after review of the CMS Developmental Screening in the First Three Years Core measure, as well as a number of additional developmental measures. The performance of these measures across Pennsylvania CHIP Contractors has been flat, and in some cases has not improved across years. Available data indicated that fewer than half of Pennsylvania children from birth to age 3 enrolled in CHIP and Medicaid in 2014 were receiving recommended screenings. Taking into account that approximately 1 in 10 Pennsylvania children may experience a delay in one or more aspects of development, this topic was selected with the aim of all children at risk are reached. The Aim Statement for the topic is “By the end of 2020 the MCO aims to increase developmental screening rates for children ages one, two and three years old.” Contractors were asked to create objectives that support this Aim Statement.

For this PIP, DHS CHIP is requiring all CHIP Contractors to submit rates at the baseline, interim, and final measurement years for “Developmental Screening the in First Three Years of Life”. Additionally, Contractors have been encouraged to consider other performance measures such as:

- Proportion of children identified at-risk for developmental, behavioral, and social delays who were referred to early intervention.
- Percentage of children and adolescents with access to primary care practitioners.
- Percentage of children with well-child visits in the first 15 months of life.

**“Improving Blood Lead Screening Rates in Children 2 Years of Age”** was selected as the result of a number of observations. Despite an overall decrease over the last 30 years in children with elevated blood lead levels in the United States, children from low-income families in specific states, including Pennsylvania, have seen decreased rates of screening of blood lead levels. Current CHIP policy requires that all children ages one and two years old and all children ages three through six without a prior lead blood test have blood levels screened consistent with current Department of Health and CDC standards. The average national lead screening rate in 2016 is 66.5%, while the Pennsylvania CHIP average is 53.2%. Despite an overall improvement in lead screening rates for Pennsylvania CHIP Contractors over the past few years, rates by Contractor and weighted average fall below the national average. In addition to the lead screening rate, Contractors have been encouraged to consider these measures as optional initiatives:

- Percentage of home investigations where lead exposure risk hazards/factors are identified,

- Total number of children successfully identified with elevated blood lead levels,
- Percent of the population under the age of five suffering from elevated blood lead levels, or
- Percent of individuals employed in the agriculture, forestry, mining, and construction industries.

The PIPs extend from January 2017 through December 2020; with research beginning in 2017, initial PIP proposals developed and submitted in second quarter 2017, and a final report due in June 2021. The non-intervention baseline period is January 2017 to December 2017. Following the formal PIP proposal, the timeline defined for the PIPs includes required interim reports in 2019 and 2020, as well as a final report in June 2021. In adherence with this timeline, all MCOs submitted their initial round of interim reports in July 2019, with review and findings administered by IPRO in Fall 2019.

All CHIP MCOs are required to submit their projects using a standardized PIP template form, which is consistent with the CMS protocol for *Conducting Performance Improvement Projects*. These protocols follow a longitudinal format and capture information relating to:

- Activity Selection and Methodology
- Data/Results
- Analysis Cycle
- Interventions

## Validation Methodology

IPRO's review evaluates each project against seven review elements:

- Element 1. Project Topic/Rationale
- Element 2. Aim
- Element 3. Methodology
- Element 4. Barrier Analysis
- Element 5. Robust Interventions
- Element 6. Results Table
- Element 7. Discussion and Validity of Reported Improvement

The first six elements relate to the baseline and demonstrable improvement phases of the project. The last element relates to sustaining improvement from the baseline measurement.

## Review Element Designation/Weighting

This section describes the scoring elements and methodology that will occur during the intervention and sustainability periods. MY 2017 is the baseline year, and during the 2019 review year, due to the several levels of feedback required, elements were reviewed and scored at multiple points during the year once interim reports were submitted in July 2019. Some MCOs received guidance towards improving their submissions in these findings, and MCOs responded accordingly with resubmission to correct specific areas.

For each review element, the assessment of compliance is determined through the weighted responses to each review item. Each element carries a separate weight. Scoring for each element is based on full, partial and non-compliance. Points are awarded for the two phases of the project noted above and combined to arrive at an overall score. The overall score is expressed in terms of levels of compliance. The elements are not formally scored beyond the full/partial/non-compliant determination.

**Table 2.1** presents the terminologies used in the scoring process, their respective definitions, and their weight percentage.

Table 2.1: Element Designation

Element Designation		
Element Designation	Definition	Weight
Full	Met or exceeded the element requirements	100%
Partial	Met essential requirements but is deficient in some areas	50%
Non-compliant	Has not met the essential requirements of the element	0%

## Scoring Matrix

When the PIPs are reviewed, all projects are evaluated for the same elements. The scoring matrix is completed for those review elements where activities have during the review year. At the time of the review, a project can be reviewed for only a subset of elements. It will then be evaluated for other elements at a later date, according to the PIP submission schedule. Some elements will be re-reviewed as applicable with each submission. At the time each element is reviewed, a finding is given of “Met”, “Partially Met”, or “Not Met”. Elements receiving a “Met” will receive 100% of the points assigned to the element, “Partially Met” elements will receive 50% of the assigned points, and “Not Met” elements will receive 0%.

## Findings

To encourage focus on improving the quality of the projects, PIPs were assessed for compliance on all applicable elements, but were not formally scored. The multiple levels of activity and collaboration between DHS, the CHIP MCOs, and IPRO continued and progressed throughout the review year.

Subsequent to MCO proposal submissions that were provided in early 2018, several levels of feedback were provided to MCOs. This feedback included:

- MCO-specific review findings for each PIP.
- Conference calls with each MCO as needed to discuss the PIP proposal review findings with key MCO staff assigned to each PIP topic.
- Information to assist MCOs in preparing their next full PIP submission for the Interim Year 1 Update, such as additional instructions regarding collection of the core required measures.

As discussed earlier, interim documents were submitted in July 2019. Review of these submissions began in August 2019 and ran through October 2019. Upon initial review of the submissions, MCOs were provided findings for each PIP with request for clarification/revision as necessary. MCOs requiring additional discussion and potential modification were contacted and advised via email of any necessary or optional changes that IPRO determined would improve the quality of their overall projects.

### Improving Developmental Screening Rate in Children Ages 1, 2, and 3 Years

UPMC provided a discussion of topic rationale at baseline, which impacts the maximum proportion of members that is feasible, while still reflecting high-volume and high-risk conditions. The discussion also included support of the topic rationale with MCO-specific data and trends, which were utilized to compare to statewide and nationwide benchmarks in assessing reasonability of the topic of Developmental Screening. It was noted during baseline review that in order to demonstrate the proposal’s potential for meaningful impact on member health, functional status, or satisfaction, more detail regarding UPMC’s pilot program should be incorporated, including MCO-specific data regarding the success of the pilot program. More data to support this project was included in the MCO’s 2019 interim report.

The aim statement, developed in 2018, specified performance indicators for improvement, which also included corresponding goals. It was noted that these goals target improvement rates in the population that should be reviewed and potentially increased for both indicators based upon CMS PIP guidance. UPMC has developed objectives that align the aim and goals with corresponding interventions in 2019.

Methodologically, UPMC developed indicators at baseline which measure changes in health status, functional status, and processes of care with strong associations with improved outcomes. The indicators themselves are defined clearly

and have been demonstrated to be measurable, as they are PA-specific and HEDIS performance measures. The study design specified data collection methods that are valid and data analysis procedures that are logical.

UPMC performed a barrier analysis at baseline which utilized primarily QI team discussions with providers to identify susceptible subpopulations, stratified by clinical characteristics. Provider input was also utilized to identify barriers, and subsequently informed the development of robust interventions. These interventions focus on provider education and outreach. It was noted during baseline review that the interventions and their tracking measures could benefit from additional information in the baseline proposal, including detailed information on provider education initiatives. More information was provided by the plan in their 2019 interim report, which further developed the project and gave detail to how the MCO plans to show improvement. In 2019, it was requested that UPMC update the Developmental Screening MY 2018 rate so that the table reflects your MCO's final reportable rates for all performance indicators for the interim period.

UPMC was asked to provide updated finalized rates for all performance indicators at baseline. Additionally, final goals and target rates were requested to be included in the results section to track progress towards goals over time.

Discussion of the success of the PIP to date was included in 2019, with relevant analyses included to note changes in performance indicators, as well as follow up activities that are planned and lessons learned from this stage of the project.

#### **Improving Blood Lead Screening Rate in Children 2 Years of Age**

UPMC provided a discussion of topic rationale in 2018, which impacts the maximum proportion of members that is feasible, while still reflecting high-volume and high-risk conditions. The discussion also included support of the topic rationale with MCO-specific data and trends, which were utilized to compare to statewide and nationwide benchmarks in assessing reasonability of the topic of Lead Screening.

The aim statement, developed at baseline, specified performance indicators for improvement with corresponding goals. These goals set a target improvement rate that is bold, feasible, and based on baseline data and strength of interventions with rationale. The objectives that the plan has highlighted align the aim and their goals with developed interventions.

Methodologically, UPMC developed indicators in 2018 which measure changes in health status, functional status, and processes of care with strong associations with improved outcomes. The indicators themselves are defined clearly and have been demonstrated to be measurable, as they are PA-specific and HEDIS performance measures. The study design specified data collection methods that are valid and data analysis procedures which are logical.

UPMC performed a barrier analysis at baseline which utilized primarily QI team discussions and literature review to identify susceptible subpopulations, stratified by clinical characteristics. Provider input was also utilized to identify barriers, and subsequently informed the development of robust interventions. These interventions focus on provider education and outreach, as well as case management review and follow up. It was noted at baseline review that the interventions and their tracking measures could benefit from additional information in the baseline proposal, including detailed information on provider education initiatives. The plan provided specific requirements for their interventions in their 2019 interim report, but it was noted that concerns around efficacy of the passive intervention and how attributable the intervention is to improved results still remain.

Discussion of the success of the PIP to date was included in 2019, with relevant analyses included to note changes in performance indicators, as well as follow up activities that are planned and lessons learned from this stage of the project.

**Table 2.1: UPMC PIP Compliance Assessments – Interim Reports**

<b>Review Element</b>	<b>Improving Developmental Screening Rate in Children Ages 1, 2, and 3 Years</b>	<b>Improving Blood Lead Screening Rate in Children 2 Years of Age</b>
Element 1. Project Topic/Rationale	Met	Met
Element 2. Aim	Met	Met
Element 3. Methodology	Met	Met
Element 4. Barrier Analysis	Met	Met
Element 5. Robust Interventions	Met	Met
Element 6. Results Table	Met	Met
Element 7. Discussion and Validity of Reported Improvement	Met	Met

### III. Performance Measures and CAHPS® Survey

#### Methodology

IPRO validated PA specific performance measures and HEDIS® data for each of the CHIP MCOs.

The MCOs were provided with final specifications for the PA Performance Measures in April 2019. Source code, raw data and rate sheets were submitted by the MCOs to IPRO for review in 2019. IPRO conducted an initial validation of each measure, including source code review and provided each MCO with formal written feedback. The MCOs were then given the opportunity for resubmission, if necessary. Source code was reviewed by IPRO. Raw data were also reviewed for reasonability and IPRO ran code against these data to validate that the final reported rates were accurate. Additionally, MCOs were provided with comparisons to the previous year’s rates and were requested to provide explanations for highlighted differences. Differences were highlighted for rates that were statistically significant and displayed at least a 3-percentage point difference in observed rates.

Evaluation of MCO performance is based on both PA-specific performance measures and selected HEDIS® measures for the EQR. The following is a list of the performance measures included in this year’s EQR report.

**Table 3.1: Performance Measure Groupings**

Source	Measures
<b>Access/Availability to Care</b>	
HEDIS®	Children and Adolescents’ Access to PCPs (Age 12 - 24 months)
HEDIS®	Children and Adolescents’ Access to PCPs (Age 25 months - 6 years)
HEDIS®	Children and Adolescents’ Access to PCPs (Age 7-11 years)
HEDIS®	Children and Adolescents’ Access to PCPs (Age 12-19 years)
<b>Well-Care Visits and Immunizations</b>	
HEDIS®	Weight assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents - Body Mass Index percentile: (Age 3-11 years)
HEDIS®	Weight assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents - Body Mass Index percentile: (Age 12-17 years)
HEDIS®	Weight assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents - Body Mass Index percentile: (Total)
HEDIS®	Weight assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents - Counseling for Nutrition: (Age 3-11 years)
HEDIS®	Weight assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents - Counseling for Nutrition: (Age 12-17 years)
HEDIS®	Weight assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents - Counseling for Nutrition: (Total)
HEDIS®	Weight assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents - Physical activity: (Age 3-11 years)
HEDIS®	Weight assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents - Physical activity: (Age 12-17 years)
HEDIS®	Weight assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents - Physical Activity: (Total)
HEDIS®	Childhood Immunization Status by Age 2 (DtaP)
HEDIS®	Childhood Immunization Status by Age 2 (IPV)
HEDIS®	Childhood Immunization Status by Age 2 (MMR)
HEDIS®	Childhood Immunization Status by Age 2 (HiB)
HEDIS®	Childhood Immunization Status by Age 2 (Hepatitis B)
HEDIS®	Childhood Immunization Status by Age 2 (VZV)
HEDIS®	Childhood Immunization Status by Age 2 (Pneumococcal Conjugate)
HEDIS®	Childhood Immunization Status by Age 2 (Hepatitis A)
HEDIS®	Childhood Immunization Status by Age 2 (Rotavirus)
HEDIS®	Childhood Immunization Status by Age 2 (Influenza)

Source	Measures
HEDIS®	Childhood Immunizations Status by Age 2 (Combination 2)
HEDIS®	Childhood Immunizations Status by Age 2 (Combination 3)
HEDIS®	Childhood Immunizations Status by Age 2 (Combination 4)
HEDIS®	Childhood Immunizations Status by Age 2 (Combination 5)
HEDIS®	Childhood Immunizations Status by Age 2 (Combination 6)
HEDIS®	Childhood Immunizations Status by Age 2 (Combination 7)
HEDIS®	Childhood Immunizations Status by Age 2 (Combination 8)
HEDIS®	Childhood Immunizations Status by Age 2 (Combination 9)
HEDIS®	Childhood Immunizations Status by Age 2 (Combination 10)
HEDIS®	Immunizations for Adolescents (Meningococcal)
HEDIS®	Immunizations for Adolescents (Tdap/Td)
HEDIS®	Immunizations for Adolescents (HPV)
HEDIS®	Immunizations for Adolescents (Combination 1)
HEDIS®	Immunizations for Adolescents (Combination 2)
<b>EPSDT: Screenings and Follow-up</b>	
HEDIS®	Lead Screening in Children (Age 2 years)
HEDIS®	Chlamydia Screening in Women (Age 16-19 years)
PA EQR	Developmental Screening in the First Three Years of Life – 1 year
PA EQR	Developmental Screening in the First Three Years of Life – 2 years
PA EQR	Developmental Screening in the First Three Years of Life – 3 years
PA EQR	Developmental Screening in the First Three Years of Life – Total
PA EQR	Contraceptive Care for All Women Most/Moderately Effective (Age 15 months – 2 years)
PA EQR	Contraceptive Care for All Women LARC (Age 15 months – 2 years)
PA EQR	Contraceptive Care for Postpartum Women Most/Moderately Effective – 3 days (Age 15 months – 20 years)
PA EQR	Contraceptive Care for Postpartum Women Most/Moderately Effective – 60 days (Age 15 months – 20 years)
PA EQR	Contraceptive Care for Postpartum Women LARC – 3 days (Age 15 months – 20 years)
PA EQR	Contraceptive Care for Postpartum Women LARC – 60 days (Age 15 months – 20 years)
<b>Dental Care for Children</b>	
HEDIS®	Annual Dental Visit (Age 2-20 years)
PA EQR	Dental Sealants for 6-9 Year Old Children at Elevated Caries Risk (CHIPRA)
PA EQR	Dental Sealants for 6-9 Year Old Children at Elevated Caries Risk (CHIPRA: Dental-Enhanced)
<b>Respiratory Conditions</b>	
HEDIS®	Appropriate Testing for Children with Pharyngitis
HEDIS®	Appropriate Treatment for Children with Upper Respiratory Infection
HEDIS®	Medication Management for People with Asthma - 50% Compliance (Age 5-11 years)
HEDIS®	Medication Management for People with Asthma - 50% Compliance (Age 12-18 years)
HEDIS®	Medication Management for People with Asthma - 50% Compliance (Age 19 years)
HEDIS®	Medication Management for People with Asthma - 50% Compliance (Total)
HEDIS®	Medication Management for People with Asthma - 75% Compliance (Age 5-11 years)
HEDIS®	Medication Management for People with Asthma - 75% Compliance (Age 12-18 years)
HEDIS®	Medication Management for People with Asthma - 75% Compliance (Age 19 years)
HEDIS®	Medication Management for People with Asthma - 75% Compliance (Total)
PA EQR	Annual Number of Asthma Patients with One or More Asthma-Related Emergency Room Visits (Age 2 – 19 years)
HEDIS®	Asthma Medication Ratio (Age 5-11 years)
HEDIS®	Asthma Medication Ratio (Age 12-18 years)
HEDIS®	Asthma Medication Ratio (Age 19 years)
HEDIS®	Asthma Medication Ratio (Total)
<b>Behavioral Health</b>	
HEDIS®	Follow-up Care for Children Prescribed Attention Deficit Hyperactivity Disorder (ADHD) – Initiation Phase
HEDIS®	Follow-up Care for Children Prescribed Attention Deficit Hyperactivity Disorder (ADHD) Medication – Continuation and Maintenance Phase
HEDIS®	Follow-Up Care After Hospitalization for Mental Illness (7 Days)
HEDIS®	Follow-Up Care After Hospitalization for Mental Illness (30 Days)



Source	Measures
HEDIS®	Metabolic Monitoring for Children and Adolescents on Antipsychotics (Age 1 – 5 years)
HEDIS®	Metabolic Monitoring for Children and Adolescents on Antipsychotics (Age 6 – 11 years)
HEDIS®	Metabolic Monitoring for Children and Adolescents on Antipsychotics (Age 12 – 17 years)
HEDIS®	Metabolic Monitoring for Children and Adolescents on Antipsychotics (Total)
HEDIS®	Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (Age 1 – 5 years)
HEDIS®	Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (Age 6 – 11 years)
HEDIS®	Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (Age 12 – 17 years)
HEDIS®	Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (Total)
HEDIS®	Use of Multiple Concurrent Antipsychotics in Children and Adolescents (Age 1 – 5 years)
HEDIS®	Use of Multiple Concurrent Antipsychotics in Children and Adolescents (Age 6 – 11 years)
HEDIS®	Use of Multiple Concurrent Antipsychotics in Children and Adolescents (Age 12 – 17 years)
HEDIS®	Use of Multiple Concurrent Antipsychotics in Children and Adolescents (Total)
<b>Utilization</b>	
HEDIS®	Well-Child Visits in the First 15 Months of Life (0 Visits)
HEDIS®	Well-Child Visits in the First 15 Months of Life (1Visits)
HEDIS®	Well-Child Visits in the First 15 Months of Life (2 Visits)
HEDIS®	Well-Child Visits in the First 15 Months of Life (3 Visits)
HEDIS®	Well-Child Visits in the First 15 Months of Life (4 Visits)
HEDIS®	Well-Child Visits in the First 15 Months of Life (5 Visits)
HEDIS®	Well-Child Visits in the First 15 Months of Life (>= 6 Visits)
HEDIS®	Well-Child Visits in the Third, Fourth, Fifth, and Sixth Years of Life (Age 3 – 6 years)
HEDIS®	Adolescent Well-Care Visits (Age 12 – 19 years)
HEDIS®	Ambulatory Care: Outpatient Visits/1000 Member Months (Ages <1 - 19 years)
HEDIS®	Ambulatory Care: Emergency Department Visits/1000 Member Months (Ages <1 - 19 years)
HEDIS®	Inpatient Utilization - General Hospital/Acute Care: Total Discharges/1000 Member Months (Ages <1 - 19 years)
HEDIS®	Inpatient Utilization - General Hospital/Acute Care: Average Length of Stay/1000 Member Months (Ages <1 - 19 years)
HEDIS®	Inpatient Utilization - General Hospital/Acute Care: Surgery Discharges /1000 Member Months (Ages <1 - 19 years)
HEDIS®	Inpatient Utilization - General Hospital/Acute Care: Surgery Average Length of Stay /1000 Member Months (Ages <1 - 19 years)
HEDIS®	Inpatient Utilization - General Hospital/Acute Care: Medicine Discharges /1000 Member Months (Ages <1 - 19 years)
HEDIS®	Inpatient Utilization - General Hospital/Acute Care: Medicine Average Length of Stay /1000 Member Months (Ages <1 - 19 years)
HEDIS®	Inpatient Utilization - General Hospital/Acute Care: Maternity /1000 Member Months (Ages 10 - 19 years)
HEDIS®	Inpatient Utilization - General Hospital/Acute Care: Maternity Average Length of Stay /1000 Member Months (Ages 10 - 19 years)
HEDIS®	Mental Health Utilization: Any Services (Ages 0 – 12 years Male and Female)
HEDIS®	Mental Health Utilization: Any Services (Ages 13 – 17 years Male and Female)
HEDIS®	Mental Health Utilization: Inpatient (Ages 0 – 12 years Male and Female)
HEDIS®	Mental Health Utilization: Inpatient (Ages 13 – 17 years Male and Female)
HEDIS®	Mental Health Utilization: Intensive Outpatient/Partial Hospitalization (Ages 0 – 12 years Male and Female)
HEDIS®	Mental Health Utilization: Intensive Outpatient/Partial Hospitalization (Ages 13 – 17 years Male and Female)
HEDIS®	Mental Health Utilization: Outpatient (Ages 0 – 12 years Male and Female)
HEDIS®	Mental Health Utilization: Outpatient (Ages 13 – 17 years Male and Female)
HEDIS®	Mental Health Utilization: Emergency Department (Ages 0 – 12 years Male and Female)
HEDIS®	Mental Health Utilization: Emergency Department (Ages 13 – 17 years Male and Female)
HEDIS®	Mental Health Utilization: Telehealth (Ages 0 – 12 years Male and Female)
HEDIS®	Mental Health Utilization: Telehealth (Ages 13 – 17 years Male and Female)
HEDIS®	Identification of Alcohol and Other Drug Services: Any Services (Ages 0 – 12 years Male and Female)
HEDIS®	Identification of Alcohol and Other Drug Services: Any Services (Ages 13 – 17 years Male and Female)
HEDIS®	Identification of Alcohol and Other Drug Services: Inpatient (Ages 0 – 12 years Male and Female)
HEDIS®	Identification of Alcohol and Other Drug Services: Inpatient (Ages 13 – 17 years Male and Female)

Source	Measures
HEDIS®	Identification of Alcohol and Other Drug Services: Intensive Outpatient/Partial Hospitalization (Ages 0 – 12 years Male and Female)
HEDIS®	Identification of Alcohol and Other Drug Services: Intensive Outpatient/Partial Hospitalization (Ages 13 – 17 years Male and Female)
HEDIS®	Identification of Alcohol and Other Drug Services: Outpatient (Ages 0 – 12 years Male and Female)
HEDIS®	Identification of Alcohol and Other Drug Services: Outpatient (Ages 13 – 17 years Male and Female)
HEDIS®	Identification of Alcohol and Other Drug Services: Emergency Department (Ages 0 – 12 years Male and Female)
HEDIS®	Identification of Alcohol and Other Drug Services: Emergency Department (Ages 13 – 17 years Male and Female)
HEDIS®	Identification of Alcohol and Other Drug Services: Telehealth (Ages 0 – 12 years Male and Female)
HEDIS®	Identification of Alcohol and Other Drug Services: Telehealth (Ages 13 – 17 years Male and Female)

## Pennsylvania (PA)-Specific Performance Measure Selection and Descriptions

Several PA-specific performance measures were calculated by each MCO and validated by IPRO. In accordance with DHS direction, IPRO created the indicator specifications to resemble HEDIS® specifications. Measures previously developed and added as mandated by CMS for children in accordance with the Children’s Health Insurance Program Reauthorization Act (CHIPRA) were continued as applicable to revised CMS specifications. New measures were developed and added in 2018 as mandated in accordance with the ACA. In 2019, no new measures were added. For each indicator, the criteria that were specified to identify the eligible population were product line, age, enrollment, anchor date, and event/diagnosis. To identify the administrative numerator positives, date of service and diagnosis/procedure code criteria were outlined, as well as other specifications, as needed. Indicator rates were calculated through one of two methods: (1) administrative, which uses only the MCOs data systems to identify numerator positives and (2) hybrid, which uses a combination of administrative data and medical record review (MRR) to identify numerator “hits” for rate calculation.

### PA Specific Administrative Measures

#### Developmental Screening in the First Three Years of Life– CHIPRA Core Set

This performance measure assesses the percentage of children screened for risk of developmental, behavioral, and social delays using a standardized screening tool in the 12 months preceding their first, second, or third birthday. Four rates, one for each group and a combined rate, are to be calculated and reported for each numerator.

#### Dental Sealants for 6-9 Year Old Children at Elevated Caries Risk – CHIPRA Core Set

This performance measure assesses the percentage of enrolled children ages 6-9 years at elevated risk of dental caries who received a sealant on a permanent first molar tooth within the measurement year.

Additionally, to be more closely aligned to the CHIPRA Core Set Measure specifications, this measure is enhanced for the state with additional available dental data (Dental-enhanced).

#### Annual Number of Asthma Patients with One or More Asthma-Related Emergency Room Visits

This performance measure assesses the percentage of children and adolescents, two years of age through 19 years of age, with an asthma diagnosis who have  $\geq 1$  emergency department (ED) visit during the measurement year.

#### Contraceptive Care for All Women – CHIPRA Core Set

This performance measure assesses the percentage of women ages 15 through 20 at risk of unintended pregnancy and were provided a most effective/moderately effective contraception method or a long-acting reversible method of contraception (LARC). For the CMS Core measures, two rates are reported: one each for (1) the provision of most/moderately effective contraception and for (2) the provision of LARC.

## **Contraceptive Care for Postpartum Women – CHIPRA Core Set**

This performance measure assesses the percentage of women ages 15 through 20 who had a live birth and were provided a most effective/moderately effective contraception method or a long-acting reversible method of contraception (LARC), within 3 days and within 60 days of delivery. For the CMS Core measures, four rates are reported in total (1) Most or moderately effective contraception – 3 days, (2) Most or moderately effective contraception – 60 days, (3) LARC – 3 days, and (4) LARC – 60 days.

## **HEDIS® Performance Measure Selection and Descriptions**

Each MCO underwent a full HEDIS® compliance audit in 2019. As indicated previously, performance on selected HEDIS® measures is included in this year’s EQR report. Development of HEDIS® measures and the clinical rationale for their inclusion in the HEDIS® measurement set can be found in HEDIS® 2019, Volume 2 Narrative. The measurement year for HEDIS® 2019 measures is 2018, as well as prior years for selected measures. Each year, DHS updates its requirements for the MCOs to be consistent with NCQA’s requirement for the reporting year. MCOs are required to report the complete set of CHIP measures, as specified in the HEDIS® Technical Specifications, Volume 2. In addition, DHS does not require the MCOs to produce the Chronic Conditions component of the CAHPS 5.0 – Child Survey.

### **Children and Adolescents’ Access to Primary Care Practitioners**

This measure assesses the percentage of members 12 months–19 years of age who had a visit with a PCP. The organization reports four separate percentages for each product line.

- Children 12–24 months and 25 months–6 years who had a visit with a PCP during the measurement year.
- Children 7–11 years and adolescents 12–19 years who had a visit with a PCP during the measurement year or the year prior to the measurement year.

### **Well-Child Visits in the First 15 Months of Life**

This measure assessed the percentage of enrollees who turned 15 months old during the measurement year, who were continuously enrolled from 31 days of age through 15 months of age who received six or more well-child visits with a PCP during their first 15 months of life.

### **Well-Child Visits in the Third, Fourth, Fifth, and Sixth Years of Life**

This measure assessed the percentage of enrollees who were 3, 4, 5, or 6 years of age during the measurement year, who were continuously enrolled during the measurement year and received one or more well-child visits with a PCP during the measurement year.

### **Childhood Immunization Status**

This measure assessed the percentage of children who turned two years of age in the measurement year who were continuously enrolled for the 12 months preceding their second birthday and who received one or both of two immunization combinations on or before their second birthday. Separate rates were calculated for each Combination. Combination 2 and 3 consists of the following immunizations:

- (4) Diphtheria and Tetanus, and Pertussis Vaccine/Diphtheria and Tetanus (DTaP/DT)
- (3) Injectable Polio Vaccine (IPV)
- (1) Measles, Mumps, and Rubella (MMR)
- (3) Haemophilus Influenza Type B (HiB)
- (3) Hepatitis B (HepB)
- (1) Chicken Pox (VZV)
- (4) Pneumococcal Conjugate Vaccine – Combination 3 only

## Adolescent Well-Care Visits

This measure assessed the percentage of enrolled members 12–21 years of age who had at least one comprehensive well-care visit with a PCP or an OB/GYN practitioner during the measurement year.

## Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents

The percentage of members 3–17 years of age who had an outpatient visit with a PCP or OB/GYN and who had evidence of the following during the measurement year.

- BMI percentile documentation.
- Counseling for nutrition.
- Counseling for physical activity

*\*Because BMI norms for youth vary with age and gender, this measure evaluates whether BMI percentile is assessed rather than an absolute BMI value.*

## Immunization for Adolescents

This measure assessed the percentage of adolescents 13 years of age who had one dose of meningococcal conjugate vaccine and one tetanus, diphtheria toxoids and acellular pertussis (Tdap) vaccine by their 13th birthday. The measure calculates a rate for each vaccine and two combination rates.

- Combination 1: Meningococcal and Tdap
- Combination 2: Meningococcal, Tdap, and HPV

## Lead Screening in Children

This measure assessed the percentage of children 2 years of age who had one or more capillary or venous lead blood tests for lead poisoning by their second birthday.

## Follow-up Care for Children Prescribed ADHD Medication

This measure assessed the percentage of children newly prescribed attention-deficit/hyperactivity disorder (ADHD) medication who had at least three follow-up care visits within a 10-month period, one of which was within 30 days of when the first ADHD medication was dispensed. Two rates are reported.

- *Initiation Phase.* The percentage of members 6–12 years of age as of the IPSPD with an ambulatory prescription dispensed for ADHD medication, who had one follow-up visit with practitioner with prescribing authority during the 30-day Initiation Phase.
- *Continuation and Maintenance (C&M) Phase.* The percentage of members 6–12 years of age as of the IPSPD with an ambulatory prescription dispensed for ADHD medication, who remained on the medication for at least 210 days and who, in addition to the visit in the Initiation Phase, had at least two follow-up visits with a practitioner within 270 days (9 months) after the Initiation Phase ended.

## Follow Up After Hospitalization for Mental Illness

The percentage of discharges for members 6 years of age and older who were hospitalized for treatment of selected mental illness diagnoses and who had a follow-up visit with a mental health practitioner. Two rates are reported.

- The percentage of discharges for which the member received follow-up within 30 days after discharge.
- The percentage of discharges for which the member received follow-up within 7 days after discharge.

### **Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics**

The percentage of children and adolescents 1–17 years of age who had a new prescription for an antipsychotic medication and had documentation of psychosocial care as first-line treatment.

### **Annual Dental Visit**

This measure assessed the percentage of children and adolescents between the ages of 2 and 20 years of age who were continuously enrolled in the MCO for the measurement year who had a dental visit during the measurement year.

### **Chlamydia Screening in Women**

This measure assessed the percentage of women 16–19 years of age who were identified as sexually active and who had at least one test for chlamydia during the measurement year.

### **Appropriate Testing for Children with Pharyngitis**

This measure assessed the percentage of children 3–18 years of age who were diagnosed with pharyngitis, dispensed an antibiotic and received a group A streptococcus (strep) test for the episode. A higher rate represents better performance (i.e., appropriate testing).

### **Appropriate Treatment for Children with Upper Respiratory Infection**

This measure assessed the percentage of children 3 months–18 years of age who were given a diagnosis of upper respiratory infection (URI) and were not dispensed an antibiotic prescription. The measure is reported as an inverted rate [ $1 - (\text{numerator}/\text{eligible population})$ ]. A higher rate indicates appropriate treatment of children with URI (i.e., the proportion for whom antibiotics were not prescribed).

### **Medication Management for People with Asthma - 75% Compliance**

This measure assessed the percentage of members 5–19 years of age during the measurement year who were identified as having persistent asthma and were dispensed appropriate medications that they remained on during the treatment period and remained on an asthma controller medication for at least 75% of their treatment period.

### **Asthma Medication Ratio – New for 2019**

This measure assessed the percentage of members 5–64 years of age who were identified as having persistent asthma and had a ratio of controller medications to total asthma medications of 0.50 or greater during the measurement year.

### **Use of Multiple Concurrent Antipsychotics in Children and Adolescents**

This measure assessed the percentage of children and adolescents 1–17 years of age who were treated with antipsychotic medications and who were on two or more concurrent antipsychotic medications for at least 90 consecutive days during the measurement year.

For this measure a lower rate indicates better performance.

### **Metabolic Monitoring for Children and Adolescents on Antipsychotics**

This measure assessed the percentage of children and adolescents 1–17 years of age who had two or more antipsychotic prescriptions and had metabolic testing.

## Additional HEDIS® Measures

Ambulatory Care, Inpatient Utilization, Mental Health Utilization, and Identification of Alcohol and Other Drug Services measures, due to differences in reporting metrics compared to the above measures, are included in Tables A1 through A4 in Appendix A of this report.

## CAHPS® Survey

The Consumer Assessment of Healthcare Providers and Systems (CAHPS) program is overseen by the Agency of Healthcare Research and Quality (AHRQ) and includes many survey products designed to capture consumer and patient perspectives on health care quality. NCQA uses the adult and child versions of the CAHPS Health Plan Surveys for HEDIS.

## Implementation of PA-Specific Performance Measures and HEDIS® Audit

The MCO successfully implemented all of the PA-specific measures for 2019 that were reported with MCO-submitted data. The MCO submitted all required source code and data for review. IPRO reviewed the source code and validated raw data submitted by the MCO. All rates submitted by the MCO were reportable. Rate calculations were collected via rate sheets and reviewed for all of the PA-specific measures.

The Contraceptive Care for All Women and Contraceptive Care for Postpartum Women (CCW; CCP) were new in 2018 for all CHIP MCOs. As in 2018, in 2019 CHIP MCOs saw very small denominators for the Contraceptive Care for Postpartum Women (CCP) measure, and thus rates are not reported for this measure across the plans. In 2019, clarification was added to note that to remain aligned with CMS specifications, the look-back period to search for exclusions is limited to the measurement year.

The Dental Sealants for 6-9 Year Old Children at Elevated Caries Risk (SEAL-CH) measure underwent some modifications in 2018. This measure was new in 2016 and several issues were discovered during the 2016 validation process. Feedback received from MCOs regarding the 2016 implementation was highlighted for discussion and led to modifications to the measure specifications for the 2017 validation process. One issue in particular was that many MCOs noted that there were providers other than the ones specified by CMS potentially applying the sealants. Based on the issues, a second numerator was developed in addition to the CMS numerator. Cases included in this numerator are cases that would not have been accepted per the CMS guidance because the provider type could not be crosswalked to an acceptable CMS provider. The second numerator was created to quantify these cases, and to provide additional information for DHS about whether sealants were being applied by providers other than those outlined by CMS, for potential future consideration when discussing the measure. There was a wide range of other providers identified across MCOs for the second numerator. Because the second numerator and the total created by adding both numerators deviate from CMS guidance, they were provided to DHS for informational purposes but are not included for reporting. The SEAL-CH and enhanced SEAL-CH rates reported in this section for are comparable to the 2016 rates and are aligned with the CMS guidance. In 2019, these changes were continued, and applicable CDT codes used for numerator compliance were updated and/or added.

The Developmental Screening in the First Three Years of Life measure was modified in 2018 in order to clarify the age cohorts that are used when reporting for this measure. This clarification noted that children can be screened in the 12 months preceding or on their 1<sup>st</sup>, 2<sup>nd</sup>, or 3<sup>rd</sup> birthday. Specifically, the member must be screened in the following timeframes in order to be compliant for their age cohort:

- Age Cohort 1: member must be screened anytime between birth to 1<sup>st</sup> birthday
- Age Cohort 2: member must be screened anytime between 1 day after 1<sup>st</sup> birthday to day of 2<sup>nd</sup> birthday
- Age Cohort 3: member must be screened anytime between 1 day after 2<sup>nd</sup> birthday to day of 3<sup>rd</sup> birthday

In 2019, these clarifications were continued forward, and additional clarification was added regarding the time period to be used for each age cohort. Specifically, the member's birthday should fall in one of the following cohorts for each numerator:

- Age Cohort 1: Children who had a claim with a relevant CPT code before or on their first birthday.
- Age Cohort 2: Children who had a claim with a relevant CPT code after their first birthday and before or on their second birthday.
- Age Cohort 3: Children who had a claim with a relevant CPT code after their second birthday and before or on their third birthday

## Findings

MCO results are presented in Tables 3.2 through 3.8. For each measure, the denominator, numerator, and measurement year rates with 95% upper and lower confidence intervals (95% CI) are presented. Confidence intervals are ranges of values that can be used to illustrate the variability associated with a given calculation. For any rate, a 95% confidence interval indicates that there is a 95% probability that the calculated rate, if it were measured repeatedly, would fall within the range of values presented for that rate. All other things being equal, if any given rate were calculated 100 times, the calculated rate would fall within the confidence interval 95 times, or 95% of the time.

Rates for both the measurement year and the previous year are presented, as available [i.e., 2019 (MY 2018) and 2018 (MY 2017)]. In addition, statistical comparisons are made between the 2019 and 2018 rates. For these year-to-year comparisons, the significance of the difference between two independent proportions was determined by calculating the z-ratio. A z-ratio is a statistical measure that quantifies the difference between two percentages when they come from two separate populations. For comparison of 2019 rates to 2018 rates, statistically significant increases are indicated by “+”, statistically significant decreases by “-” and no statistically significant change by “n.s.”.

In addition to each individual MCOs rate, the MMC average for 2019 (MY 2018) is presented. The MMC average is a weighted average, which is an average that takes into account the proportional relevance of each MCO. Each table also presents the significance of difference between the plan’s measurement year rate and the MMC average for the same year. For comparison of 2019 rates to MMC rates, the “+” symbol denotes that the plan rate exceeds the MMC rate; the “-” symbol denotes that the MMC rate exceeds the plan rate and “n.s.” denotes no statistically significant difference between the two rates. Rates for the HEDIS® measures were compared to corresponding Medicaid percentiles; comparison results are provided in the tables. The 90<sup>th</sup> percentile is the benchmark for the HEDIS® measures.

Note that the large denominator sizes for many of the analyses led to increased statistical power, and thus contributed to detecting statistical differences that are not clinically meaningful. For example, even a 1-percentage point difference between two rates was statistically significant in many cases, although not meaningful. Hence, results corresponding to each table highlight only differences that are both statistically significant, and display at least a 3-percentage point difference in observed rates. It should also be mentioned that when the denominator sizes are small, even relatively large differences in rates may not yield statistical significance due to reduced power; if statistical significance is not achieved, results will not be highlighted in the report. Differences are also not discussed if the denominator was less than 30 for a particular rate, in which case, “NA” (Not Applicable) appears in the corresponding cells. However, “NA” (Not Available) also appears in the cells under the HEDIS® 2019 percentile column for PA-specific measures that do not have HEDIS® percentiles to compare.

The tables below show rates up to one decimal place. Calculations to determine differences between rates are based upon unrounded rates. Due to rounding, differences in rates that are reported in the narrative may differ slightly from the difference between the rates as presented in the table.

Graphical representation of findings is provided for a subset of measures with sufficient data to provide informative illustration to the tables provided below. These can be found in the appendix.

## Access to/Availability of Care

Strengths are identified for the following 2019 (MY 2018) Access to/Availability of Care performance measures.

- The following rates are statistically significantly above/better than the 2019 MMC weighted average:

- Children and Adolescents' Access to PCPs (Age 25 months-6 years)

No opportunities for improvement are identified for 2019 (MY 2018) Access/Availability of Care performance measures.

**Table 3.2: Access to Care**

Indicator		2019 (MY 2018)					Rate Comparison				
Source	Name	Denom	Num	Rate	Lower 95% Confidence Limit	Upper 95% Confidence Limit	2018 (MY2017) Rate	2019 Rate Compared to 2018	MMC	2019 Rate Compared to MMC	HEDIS 2019 percentile
HEDIS	Children and Adolescents' Access To PCP (12-24 Months)	315	313	99.4%	98.3%	100.0%	99.7%	n.s.	97.9%	n.s.	>= 90th percentile
HEDIS	Children and Adolescents' Access To PCP (25 Months-6 Yrs)	5,801	5,721	98.6%	98.3%	98.9%	95.7%	+	94.1%	+	>= 90th percentile
HEDIS	Children and Adolescents' Access To PCP (7-11 Yrs)	5,264	5,100	96.9%	96.4%	97.4%	97.0%	n.s.	96.6%	n.s.	>= 90th percentile
HEDIS	Children and Adolescents' Access To PCP (12-19 Yrs)	7,196	6,929	96.3%	95.8%	96.7%	96.3%	n.s.	96.3%	n.s.	>= 90th percentile

### Well-Care Visits and Immunizations

Strengths are identified for the following 2019 (MY 2018) Well-Care Visits and Immunizations performance measures.

- The following rates are statistically significantly above/better than the 2019 MMC weighted average:
  - Childhood Immunization Status - Hepatitis B
  - Childhood Immunization Status - Hepatitis A
  - Childhood Immunization Status - Rotavirus
  - Childhood Immunization Status - Combo 4
  - Childhood Immunization Status - Combo 5
  - Childhood Immunization Status - Combo 7
  - Childhood Immunization Status - Combo 8
  - Childhood Immunization Status - Combo 9
  - Childhood Immunization Status - Combo 10

Opportunities for improvement are identified for the following Well-Care Visits and Immunizations performance measures:

- The following rates are statistically significantly below/worse than the 2019 MMC weighted average:
  - Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents - BMI percentile (12-17 years)
  - Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents - Counseling for Nutrition (12-17 years)
  - Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents - Counseling for Physical Activity (12-17 years)

**Table 3.3: Well-Care Visits and Immunizations**

Indicator		2019 (MY 2018)					Rate Comparison				
Source	Name	Denom	Num	Rate	Lower 95% Confidence Limit	Upper 95% Confidence Limit	2018 (MY2017) Rate	2018 Rate Compared to 2017	MMC	2019 Rate Compared to MMC	HEDIS 2019 percentile
HEDIS	Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents - BMI percentile (3-11 years)	11,435	167	83.9%	83.2%	84.6%	80.9%	+	84.4%	-	>= 50th and < 75th percentile
HEDIS	Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents - BMI percentile (12-17 years)	7,676	111	77.6%	76.7%	78.6%	79.0%	-	82.2%	-	>= 25th and < 50th percentile
HEDIS	Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents - BMI percentile (Total)	19,111	278	81.3%	80.7%	81.8%	80.3%	+	83.5%	-	>= 50th and < 75th percentile
HEDIS	Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents - Counseling for Nutrition (3-11 years)	11,435	156	78.4%	77.6%	79.2%	78.0%	+	78.9%	-	>= 50th and < 75th percentile



Indicator		2019 (MY 2018)					Rate Comparison				
Source	Name	Denom	Num	Rate	Lower 95% Confidence Limit	Upper 95% Confidence Limit	2018 (MY2017) Rate	2018 Rate Compared to 2017	MMC	2019 Rate Compared to MMC	HEDIS 2019 percentile
HEDIS	Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents - Counseling for Nutrition (12-17 years)	7,676	102	71.3%	70.3%	72.3%	71.4%	n.s.	75.6%	-	>= 50th and < 75th percentile
HEDIS	Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents - Counseling for Nutrition (Total)	19,111	258	75.4%	74.8%	76.1%	75.8%	-	77.5%	-	>= 50th and < 75th percentile
HEDIS	Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents - Counseling for Physical Activity (3-11 years)	11,435	149	74.9%	74.1%	75.7%	73.9%	+	73.4%	+	>= 75th and < 90th percentile
HEDIS	Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents - Counseling for Physical Activity (12-17 years)	7,676	99	69.2%	68.2%	70.3%	67.2%	+	76.4%	-	>= 50th and < 75th percentile
HEDIS	Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents - Counseling for Physical Activity (Total)	19,111	248	72.5%	71.9%	73.2%	71.7%	+	74.6%	-	>= 50th and < 75th percentile
HEDIS	Childhood Immunization Status - DTaP	649	361	87.8%	85.2%	90.4%	86.1%	n.s.	86.7%	n.s.	>= 90th percentile
HEDIS	Childhood Immunization Status - IPV	649	388	94.4%	92.6%	96.2%	91.7%	n.s.	92.6%	n.s.	>= 90th percentile
HEDIS	Childhood Immunization Status - MMR	649	388	94.4%	92.6%	96.2%	92.2%	n.s.	91.6%	n.s.	>= 90th percentile
HEDIS	Childhood Immunization Status - HiB	649	385	93.7%	91.7%	95.6%	92.9%	n.s.	92.2%	n.s.	>= 90th percentile
HEDIS	Childhood Immunization Status - Hepatitis B	649	393	95.6%	94.0%	97.3%	90.3%	n.s.	91.6%	+	>= 90th percentile
HEDIS	Childhood Immunization Status - VZV	649	385	93.7%	91.7%	95.6%	91.7%	n.s.	91.1%	n.s.	>= 90th percentile
HEDIS	Childhood Immunization Status - Pneumococcal Conjugate	649	370	90.0%	87.6%	92.4%	86.9%	n.s.	87.2%	n.s.	>= 90th percentile
HEDIS	Childhood Immunization Status - Hepatitis A	649	378	92.0%	89.8%	94.1%	89.3%	n.s.	87.4%	+	>= 90th percentile
HEDIS	Childhood Immunization Status - Rotavirus	649	353	85.9%	83.1%	88.6%	81.3%	n.s.	79.1%	+	>= 90th percentile
HEDIS	Childhood Immunization Status - Influenza	649	255	62.0%	58.2%	65.9%	59.1%	n.s.	58.9%	n.s.	>= 90th percentile
HEDIS	Childhood Immunization Status - Combo 2	649	351	85.4%	82.6%	88.2%	82.0%	n.s.	82.2%	n.s.	>= 90th percentile
HEDIS	Childhood Immunization Status - Combo 3	649	344	83.7%	80.8%	86.6%	79.6%	n.s.	80.1%	n.s.	>= 90th percentile
HEDIS	Childhood Immunization Status - Combo 4	649	337	82.0%	79.0%	85.0%	77.6%	n.s.	77.1%	+	>= 90th percentile
HEDIS	Childhood Immunization Status - Combo 5	649	320	77.9%	74.6%	81.1%	72.7%	n.s.	70.5%	+	>= 90th percentile
HEDIS	Childhood Immunization Status - Combo 6	649	236	57.4%	53.5%	61.3%	53.5%	n.s.	53.5%	n.s.	>= 90th percentile
HEDIS	Childhood Immunization Status - Combo 7	649	318	77.4%	74.1%	80.7%	71.8%	+	68.6%	+	>= 90th percentile
HEDIS	Childhood Immunization Status - Combo 8	649	234	56.9%	53.0%	60.8%	53.5%	n.s.	52.7%	+	>= 90th percentile
HEDIS	Childhood Immunization Status - Combo 9	649	230	56.0%	52.1%	59.9%	49.6%	+	49.0%	+	>= 90th percentile
HEDIS	Childhood Immunization Status - Combo 10	649	229	55.7%	51.8%	59.6%	49.6%	+	48.2%	+	>= 90th percentile
HEDIS	Immunizations for Adolescents - Meningococcal	1,435	393	95.6%	94.5%	96.7%	90.3%	+	92.7%	+	>= 90th percentile
HEDIS	Immunizations for Adolescents - Tdap	1,435	394	95.9%	94.8%	96.9%	93.4%	n.s.	93.8%	n.s.	>= 90th percentile
HEDIS	Immunizations for Adolescents - HPV	1,435	143	34.8%	32.3%	37.3%	25.8%	+	35.6%	n.s.	>= 25th and < 50th percentile
HEDIS	Immunizations for Adolescents - Combination 1	1,435	388	94.4%	93.2%	95.6%	90.0%	+	91.4%	+	>= 90th percentile
HEDIS	Immunizations for Adolescents - Combination 2	1,435	138	33.6%	31.1%	36.1%	24.3%	+	34.2%	n.s.	>= 25th and < 50th percentile

## EPSDT/Bright Futures: Screenings and Follow-up

Strengths are identified for the following 2019 (MY 2018) Dental Care for Children performance measures.

- The following rates are statistically significantly above/better than the 2019 MMC weighted average:
  - Lead Screening in Children (Age 2 years)
  - Developmental Screening in the First Three Years of Life - Total
  - Developmental Screening in the First Three Years of Life - 1 year
  - Developmental Screening in the First Three Years of Life - 2 years
  - Developmental Screening in the First Three Years of Life - 3 years
  - Contraceptive Care for All Women (Age 15 – 20 years): Most or Moderately Effective

Opportunities for improvement are identified for the following EPSDT: Screenings and Follow-up performance measures:

- The following rates are statistically significantly below/worse than the 2019 MMC weighted average:
  - Chlamydia Screening in Women (16-20)
  - Chlamydia Screening in Women - Total

**Table 3.4: EPSDT/Bright Futures: Screenings and Follow-up**

Indicator		2019 (MY 2018)					Rate Comparison				
Source	Name	Denom	Num	Rate	Lower 95% Confidence Limit	Upper 95% Confidence Limit	2018 (MY2017) Rate	2019 Rate Compared to 2018	MMC	2019 Rate Compared to MMC	HEDIS 2019 percentile
HEDIS	Lead Screening in Children	649	329	80.0%	76.9%	83.2%	65.2%	+	66.1%	+	>= 50th and < 75th percentile
HEDIS	Chlamydia Screening in Women (16-20)	1,029	376	36.5%	33.5%	39.5%	33.0%	n.s.	42.6%	-	< 10th percentile
HEDIS	Chlamydia Screening in Women - Total	1,029	376	36.5%	33.5%	39.5%	33.0%	n.s.	42.6%	-	< 10th percentile
PA EQR	Developmental Screening in the First Three Years of Life – 1 year	1,853	1,245	67.2%	65.0%	69.4%	61.2%	+	56.0%	+	NA
PA EQR	Developmental Screening in the First Three Years of Life – 2 years	130	89	68.5%	60.1%	76.8%	56.4%	+	50.3%	+	NA
PA EQR	Developmental Screening in the First Three Years of Life – 3 years	648	445	68.7%	65.0%	72.3%	65.0%	n.s.	58.3%	+	NA
PA EQR	Developmental Screening in the First Three Years of Life – Total	1,075	711	66.1%	63.3%	69.0%	59.7%	+	55.1%	+	NA
PA EQR	Contraceptive Care for All Women (Age 15 – 20 years): Most or Moderately Effective	2,839	954	33.6%	31.8%	35.4%	13.1%	+	28.2%	+	NA
PA EQR	Contraceptive Care for All Women (Age 15 – 20 years): LARC	2,839	67	2.4%	1.8%	2.9%	3.7%	-	1.9%	n.s.	NA
PA EQR	Contraceptive Care for Postpartum Women (Age 15 – 20 years): Most or moderately effective contraception – 3 days	9	0	NA	NA	NA	NA	NA	5.9%	NA	NA
PA EQR	Contraceptive Care for Postpartum Women (Age 15 – 20 years): Most or moderately effective contraception – 60 days	9	4	NA	NA	NA	NA	NA	43.1%	NA	NA
PA EQR	Contraceptive Care for Postpartum Women (Age 15 – 20 years): LARC – 3 days	9	0	NA	NA	NA	NA	NA	3.9%	NA	NA
PA EQR	Contraceptive Care for Postpartum Women (Age 15 – 20 years): LARC – 60 days	9	3	NA	NA	NA	NA	NA	19.6%	NA	NA

## Dental Care for Children

Strengths are identified for the following 2019 (MY 2018) Dental Care for Children performance measures.

- The following rates are statistically significantly above/better than the 2019 MMC weighted average:
  - Dental Sealants for 6-9 Year Of Children At Elevated Caries Risk
  - Dental Sealants for 6-9 Year Of Children At Elevated Caries Risk (Dental Enhanced)

Opportunities for improvement are identified for the following Dental Care for Children performance measures:

- The following rates are statistically significantly below/worse than the 2019 MMC weighted average:
  - Annual Dental Visit (2-3 Yrs)

- Annual Dental Visit (15-18 Yrs)

**Table 3.5: Dental Care for Children**

Indicator		2019 (MY 2018)					Rate Comparison					
Source	Name	Denom	Num	Rate	Lower 95% Confidence Limit	Upper 95% Confidence Limit	2018 (MY2017) Rate	2019 Rate Compared to 2018	MMC	2019 Rate Compared to MMC	HEDIS 2019 percentile	
HEDIS	Annual Dental Visit (2-3 Yrs)	2,165	916	42.3%	40.2%	44.4%	41.3%	n.s.	48.0%	-	>= 50th and < 75th percentile	
HEDIS	Annual Dental Visit (4-6 Yrs)	3,703	2,779	75.0%	73.6%	76.5%	75.8%	n.s.	75.9%	n.s.	>= 75th and < 90th percentile	
HEDIS	Annual Dental Visit (7-10 Yrs)	6,459	4,920	76.2%	75.1%	77.2%	76.9%	n.s.	78.7%	-	>= 75th and < 90th percentile	
HEDIS	Annual Dental Visit (11-14 Yrs)	6,347	4,606	72.6%	71.5%	73.7%	72.1%	n.s.	75.2%	-	>= 75th and < 90th percentile	
HEDIS	Annual Dental Visit (15-18 Yrs)	5,710	3,596	63.0%	61.7%	64.2%	64.0%	n.s.	66.0%	-	>= 75th and < 90th percentile	
HEDIS	Annual Dental Visit (19-20 Yrs)	76	39	51.3%	39.4%	63.2%	63.2%	n.s.	54.3%	n.s.	>= 90th percentile	
HEDIS	Annual Dental Visit (Total)	24,460	16,856	68.9%	68.3%	69.5%	69.3%	n.s.	71.8%	-	>= 75th and < 90th percentile	
PA EQR	Dental Sealants for 6-9 Year Old Children at Elevated Caries Risk (CHIPRA)	3,440	911	26.5%	25.0%	28.0%	27.1%	n.s.	18.9%	+	NA	
PA EQR	Dental Sealants for 6-9 Year Old Children at Elevated Caries Risk (CHIPRA: Dental-Enhanced)	3,517	920	26.2%	24.7%	27.6%	27.0%	n.s.	19.2%	+	NA	

Note: The ADV 19-20 year old age cohort is reported here as only 19 year olds, in order to include only members that are CHIP eligible.

## Respiratory Conditions

Strengths are identified for the following 2019 (MY 2018) Respiratory performance measures.

- The following rates are statistically significantly above/better than the 2019 MMC weighted average:
  - Annual Number of Asthma Patients with One or More Asthma-Related Emergency Room Visits (Age 2 – 19 years)
  - Asthma Medication Ratio - 5 - 11 years

No opportunities for improvement are identified for 2019 (MY 2018) Respiratory Conditions performance measures.

**Table 3.6: Respiratory Conditions**

Indicator		2019 (MY 2018)					Rate Comparison					
Source	Name	Denom	Num	Rate	Lower 95% Confidence Limit	Upper 95% Confidence Limit	2018 (MY2017) Rate	2019 Rate Compared to 2018	MMC	2019 Rate Compared to MMC	HEDIS 2019 percentile	
HEDIS	Appropriate Testing for Children With Pharyngitis	2,274	2,050	90.1%	88.9%	91.4%	90.2%	n.s.	87.3%	+	>= 75th and < 90th percentile	
HEDIS	Appropriate Treatment for Children With Upper Respiratory Infection <sup>1</sup>	1,938	221	88.6%	87.2%	90.0%	88.0%	n.s.	90.4%	-	>= 25th and < 50th percentile	
HEDIS	Medication Management for People with Asthma - 50% Compliance (Age 5-11 years)	147	95	64.6%	56.6%	72.7%	55.0%	n.s.	61.9%	n.s.	NA	
HEDIS	Medication Management for People with Asthma - 50% Compliance (Age 12-18 years)	142	80	56.3%	47.8%	64.8%	60.0%	n.s.	58.8%	n.s.	NA	
HEDIS	Medication Management for People with Asthma - 50% Compliance (Total)	289	175	60.6%	54.7%	66.4%	57.3%	n.s.	60.4%	n.s.	NA	
HEDIS	Medication Management for People With Asthma - Medication Compliance 75% (5-11)	147	52	35.4%	27.3%	43.4%	29.8%	n.s.	37.6%	n.s.	>= 50th and < 75th percentile	
HEDIS	Medication Management for People With Asthma - Medication Compliance 75% (12-18)	142	46	32.4%	24.3%	40.4%	36.8%	n.s.	35.3%	n.s.	>= 50th and < 75th percentile	
HEDIS	Medication Management for People With Asthma - Medication Compliance 75% (Total)	289	98	33.9%	28.3%	39.5%	33.1%	n.s.	36.4%	n.s.	>= 25th and < 50th percentile	
PA EQR	Annual Number of Asthma Patients with One or More Asthma-Related Emergency Room Visits (Age 2 – 19 years)	2,652	181	6.8%	5.9%	7.8%	7.1%	n.s.	10.0%	-	NA	
HEDIS	Asthma Medication Ratio - 5 - 11 years	154	135	87.7%	82.1%	93.2%	NA	NA	77.2%	+	>= 90th percentile	
HEDIS	Asthma Medication Ratio - 12 - 18 years	160	107	66.9%	59.3%	74.5%	NA	NA	70.2%	n.s.	>= 50th and < 75th percentile	

Indicator		2019 (MY 2018)						Rate Comparison			
Source	Name	Denom	Num	Rate	Lower 95% Confidence Limit	Upper 95% Confidence Limit	2018 (MY2017) Rate	2019 Rate Compared to 2018	MMC	2019 Rate Compared to MMC	HEDIS 2019 percentile
HEDIS	Asthma Medication Ratio - 19 years	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
HEDIS	Asthma Medication Ratio - Total	314	242	77.1%	72.3%	81.9%	NA	NA	73.9%	n.s.	>= 90th percentile

<sup>1</sup> Per NCQA, a higher rate indicates appropriate treatment of children with URI (i.e., the proportion for whom antibiotics were not prescribed).

Note: Although reporting for age cohort 19 - 50 year olds for the MMA measure, it is not included in CHIP reporting as most members in this cohort are not eligible for CHIP based on age.

## Behavioral Health

Strengths are identified for the following 2019 (MY 2018) Behavioral Health performance measures.

- The following rates are statistically significantly above/better than the 2019 MMC weighted average:
  - Follow Up Care for Children Prescribed ADHD Medication - Initiation Phase
  - Follow Up After Hospitalization For Mental Illness - 7 days
  - Follow Up After Hospitalization For Mental Illness - 30 days

No opportunities for improvement are identified for 2019 (MY 2018) Behavioral Health performance measures.

**Table 3.7: Behavioral Health**

Indicator		2019 (MY 2018)						Rate Comparison			
Source	Name	Denom	Num	Rate	Lower 95% Confidence Limit	Upper 95% Confidence Limit	2018 (MY2017) Rate	2019 Rate Compared to 2018	MMC	2019 Rate Compared to MMC	HEDIS 2019 percentile
HEDIS	Follow Up Care for Children Prescribed ADHD Medication - Initiation Phase	269	162	60.2%	54.2%	66.3%	63.7%	n.s.	49.0%	+	>= 90th percentile
HEDIS	Follow Up Care for Children Prescribed ADHD Medication - Continuation & Maintenance Phase	95	64	67.4%	57.4%	77.3%	78.0%	n.s.	63.7%	n.s.	>= 75th and < 90th percentile
HEDIS	Follow Up After Hospitalization For Mental Illness - 7 days	123	72	58.5%	49.4%	67.6%	59.7%	n.s.	46.9%	+	>= 75th and < 90th percentile
HEDIS	Follow Up After Hospitalization For Mental Illness - 30 days	123	99	80.5%	73.1%	87.9%	85.1%	n.s.	69.9%	+	>= 75th and < 90th percentile
HEDIS	Metabolic Monitoring for Children and Adolescents on Antipsychotics (6-11 years)	0	0	NA	NA	NA	NA	NA	NA	NA	NA
HEDIS	Metabolic Monitoring for Children and Adolescents on Antipsychotics (1-5 Years)	8	5	NA	NA	NA	NA	NA	NA	NA	NA
HEDIS	Metabolic Monitoring for Children and Adolescents on Antipsychotics (12-17 years)	37	12	32.4%	16.0%	48.9%	NA	NA	37.0%	n.s.	>= 25th and < 50th percentile
HEDIS	Metabolic Monitoring for Children and Adolescents on Antipsychotics (Total)	45	17	37.8%	22.5%	53.1%	52.5%	n.s.	42.9%	n.s.	>= 50th and < 75th percentile
HEDIS	Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (1-5 Years)	0	-	NA	NA	NA	NA	NA	NA	NA	NA
HEDIS	Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (6-11 years)	7	1	NA	NA	NA	NA	NA	NA	NA	NA
HEDIS	Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (12-17 years)	28	1	NA	NA	NA	NA	NA	NA	NA	NA
HEDIS	Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (Total)	35	1	68.6%	51.8%	85.4%	63.6%	n.s.	68.6%	n.s.	>= 75th and < 90th percentile
HEDIS	Use of Multiple Concurrent Antipsychotics in Children and Adolescents (1-5 Years)	0	-	NA	NA	NA	NA	NA	NA	NA	NA
HEDIS	Use of Multiple Concurrent Antipsychotics in Children and Adolescents (6-11 years)	7	0	NA	NA	NA	NA	NA	NA	NA	NA
HEDIS	Use of Multiple Concurrent Antipsychotics in Children and Adolescents (12-17 years)	20	0	NA	NA	NA	NA	NA	NA	NA	NA
HEDIS	Use of Multiple Concurrent Antipsychotics in Children and Adolescents (Total)	27	0	NA	NA	NA	0.0%	NA	NA	NA	NA

## Utilization

No strengths are identified for the 2019 (MY 2018) Utilization performance measures.

No Opportunities for improvement are identified for the 2019 (MY 2018) Utilization performance measures.

**Table 3.8: Utilization**

Source	Indicator Name	2019 (MY 2018)					Rate Comparison					
		Denom	Num	Rate	Lower 95% Confidence Limit	Upper 95% Confidence Limit	2018 (MY2017) Rate	2019 Rate Compared to 2018	MMC	2019 Rate Compared to MMC	HEDIS 2019 percentile	
HEDIS	Well-Child Visits in the first 15 Months of Life (0 visits)	166	0	0.0%	0.0%	0.3%	0.5%	n.s.	0.2%	n.s.	NA	
HEDIS	Well-Child Visits in the first 15 Months of Life (1 visit)	166	0	0.0%	0.0%	0.3%	0.0%	NA	0.0%	NA	NA	
HEDIS	Well-Child Visits in the first 15 Months of Life (2 visits)	166	2	1.2%	0.0%	3.2%	0.0%	n.s.	0.4%	n.s.	< 10th percentile	
HEDIS	Well-Child Visits in the first 15 Months of Life (3 visits)	166	1	0.6%	0.0%	2.1%	0.0%	n.s.	1.1%	n.s.	< 10th percentile	
HEDIS	Well-Child Visits in the first 15 Months of Life (4 visits)	166	0	0.0%	0.0%	0.3%	2.4%	-	2.9%	-	NA	
HEDIS	Well-Child Visits in the first 15 Months of Life (5 visits)	166	22	13.3%	7.8%	18.7%	17.1%	n.s.	13.7%	n.s.	>= 25th and < 50th percentile	
HEDIS	Well-Child Visits in the first 15 Months of Life (6 or more visits)	166	141	84.9%	79.2%	90.7%	80.0%	n.s.	81.7%	n.s.	>= 90th percentile	
HEDIS	Well-Child Visits in the 3rd, 4th, 5th, and 6th Years of Life	4,893	137	86.2%	85.2%	87.1%	90.4%	-	84.0%	-	>= 90th percentile	
HEDIS	Adolescent Well-Care Visits	10,544	253	69.1%	68.2%	70.0%	67.8%	-	70.2%	-	>= 90th percentile	
HEDIS	AMBA: Outpatient Visits/1000 MM Ages <1 year	3,811	3,125	819.99	NA	NA	796.01	-	727.44	-	>= 90th percentile	
HEDIS	AMBA: Outpatient Visits/1000 MM Ages 1 - 9 years	211,006	68,690	325.54	NA	NA	318.46	-	273.40	-	>= 90th percentile	
HEDIS	AMBA: Outpatient Visits/1000 MM Ages 10 - 19 years	233,759	68,274	292.07	NA	NA	262.05	-	237.76	-	>= 90th percentile	
HEDIS	AMBA: Outpatient Visits/1000 MM Ages <1 - 19 years Total Rate	448,576	140,089	312.30	NA	NA	293.44	-	257.32	-	>= 90th percentile	
HEDIS	AMBA: Emergency Department Visits/1000 MM Ages <1 year	3,811	170	44.61	NA	NA	46.89	-	40.21	-	>= 90th percentile	
HEDIS	AMBA: Emergency Department Visits/1000 MM Ages 1 - 9 years	211,006	6,982	33.09	NA	NA	34.09	-	30.21	-	>= 90th percentile	
HEDIS	AMBA: Emergency Department Visits/1000 MM Ages 10 - 19 years	233,759	6,827	29.21	NA	NA	30.86	-	25.12	-	>= 90th percentile	
HEDIS	AMBA: Emergency Department Visits/1000 MM Ages <1 - 19 years Total Rate	448,576	13,979	31.16	NA	NA	32.54	-	27.52	-	>= 90th percentile	
HEDIS	IPUA: Total Discharges/1000 MM Ages <1 year	3,811	19	4.99	NA	NA	3.52	-	NA	NA	NA	
HEDIS	IPUA: Total Discharges/1000 MM Ages 1 - 9 years	211,006	161	0.76	76.1%	76.5%	0.65	-	NA	NA	NA	
HEDIS	IPUA: Total Discharges/1000 MM Ages 10 - 19 years	233,759	224	0.96	95.7%	95.9%	0.89	-	NA	NA	NA	
HEDIS	IPUA: Total Discharges/1000 MM Ages <1 - 19 years Total Rate	448,576	404	0.90	90.0%	90.2%	0.80	-	NA	NA	NA	
HEDIS	IPUA: Total Inpatient ALOS Ages <1 year	19	41	2.16	NA	NA	3.50	NA	NA	NA	NA	
HEDIS	IPUA: Total Inpatient ALOS Ages 1 - 9 Years	161	463	2.88	NA	NA	3.28	NA	NA	NA	NA	
HEDIS	IPUA: Total Inpatient ALOS Ages 10 - 19 years	224	853	3.81	NA	NA	3.41	NA	NA	NA	NA	
HEDIS	IPUA: Total Inpatient ALOS Ages <1 - 19 years Total Rate	404	1,357	3.36	NA	NA	3.36	NA	NA	NA	NA	
HEDIS	IPUA: Surgery Discharges/1000 MM Ages <1 year	3,811	7	1.84	NA	NA	0.59	-	NA	NA	NA	
HEDIS	IPUA: Surgery Discharges/1000 MM Ages 1 - 9 years	211,006	55	0.26	25.9%	26.3%	0.20	-	NA	NA	NA	
HEDIS	IPUA: Surgery Discharges/1000 MM Ages 10 - 19 years	233,759	81	0.35	34.5%	34.8%	0.32	-	NA	NA	NA	
HEDIS	IPUA: Surgery Discharges/1000 MM Ages <1 - 19 years Total Rate	448,576	143	0.32	31.7%	32.0%	0.26	-	NA	NA	NA	
HEDIS	IPUA: Surgery ALOS Ages <1 year	7	15	2.14	NA	NA	1.50	NA	NA	NA	NA	
HEDIS	IPUA: Surgery ALOS Ages 1 - 9 years	55	217	3.95	NA	NA	5.02	NA	NA	NA	NA	
HEDIS	IPUA: Surgery ALOS Ages 10 - 19 years	81	483	5.96	NA	NA	4.42	NA	NA	NA	NA	
HEDIS	IPUA: Surgery ALOS Ages <1 - 19 years Total Rate	143	715	5.00	NA	NA	4.59	NA	NA	NA	NA	
HEDIS	IPUA: Medicine Discharges/1000 MM Ages <1 year	3,811	12	3.15	NA	NA	2.93	-	NA	NA	NA	
HEDIS	IPUA: Medicine Discharges/1000 MM Ages 1 - 9 years	211,006	106	0.50	50.0%	50.4%	0.45	-	NA	NA	NA	
HEDIS	IPUA: Medicine Discharges/1000 MM Ages 10 - 19 years	233,759	124	0.53	52.8%	53.2%	0.48	-	NA	NA	NA	
HEDIS	IPUA: Medicine Discharges/1000 MM Ages <1 - 19 years Total Rate	448,576	242	0.54	53.8%	54.1%	0.49	-	NA	NA	NA	
HEDIS	IPUA: Medicine ALOS Ages <1 year	12	26	2.17	NA	NA	3.90	NA	NA	NA	NA	
HEDIS	IPUA: Medicine ALOS Ages 1 - 9 years	106	246	2.32	NA	NA	2.53	NA	NA	NA	NA	
HEDIS	IPUA: Medicine ALOS Ages 10 - 19 years	124	332	2.68	NA	NA	2.66	NA	NA	NA	NA	
HEDIS	IPUA: Medicine ALOS Ages <1 - 19 years Total Rate	242	604	2.50	NA	NA	2.66	NA	NA	NA	NA	
HEDIS	IPUA: Maternity/1000 MM Ages 10 - 19 years	233,759	19	0.08	8.0%	8.2%	0.09	-	NA	NA	NA	

Indicator		2019 (MY 2018)					Rate Comparison				
Source	Name	Denom	Num	Rate	Lower 95% Confidence Limit	Upper 95% Confidence Limit	2018 (MY2017) Rate	2019 Rate Compared to 2018	MMC	2019 Rate Compared to MMC	HEDIS 2019 percentile
HEDIS	IPIUA: Maternity ALOS Ages 10 - 19 years Total Rate	19	38	2.00	NA	NA	3.85	NA		NA	NA
HEDIS	MPT: Any Services Ages 0 - 12 years - Male	150,301	1,314	10.49%	10.3%	10.6%	10.56%	-		NA	NA
HEDIS	MPT: Any Services MM Ages 0 - 12 years - Female	147,633	942	7.66%	7.5%	7.8%	7.07%	-		NA	NA
HEDIS	MPT: Any Services Ages 0 - 12 years - Total Rate	297,934	2,256	9.09%	9.0%	9.2%	8.83%	-		NA	NA
HEDIS	MPT: Any Services Ages 13 - 17 years - Male	64,215	732	13.68%	13.4%	13.9%	13.30%	-		NA	NA
HEDIS	MPT: Any Services Ages 13 - 17 years - Female	63,725	1,187	22.35%	22.0%	22.7%	20.62%	-		NA	NA
HEDIS	MPT: Any Services Ages 13 - 17 years - Total Rate	127,940	1,919	18.00%	17.8%	18.2%	16.97%	-		NA	NA
HEDIS	MPT: Inpatient Ages 0 - 12 years - Male	150,301	14	0.11%	0.1%	0.1%	0.08%	-		NA	NA
HEDIS	MPT: Inpatient Ages 0 - 12 years - Female	147,633	9	0.07%	0.1%	0.1%	0.09%	-		NA	NA
HEDIS	MPT: Inpatient Ages 0 - 12 years - Total Rate	297,934	23	0.09%	0.1%	0.1%	0.09%	-		NA	NA
HEDIS	MPT: Inpatient Ages 13 - 17 years - Male	64,215	34	0.64%	0.6%	0.7%	0.70%	-		NA	NA
HEDIS	MPT: Inpatient Ages 13 - 17 years - Female	63,725	75	1.41%	1.3%	1.5%	1.49%	-		NA	NA
HEDIS	MPT: Inpatient Ages 13 - 17 years - Total Rate	127,940	109	1.02%	1.0%	1.1%	1.10%	-		NA	NA
HEDIS	MPT: Intensive Outpatient/Partial Hospitalization Ages 0 - 12 years - Male	150,301	15	0.12%	0.1%	0.1%	0.25%	-		NA	NA
HEDIS	MPT: Intensive Outpatient/Partial Hospitalization Ages 0 - 12 years - Female	147,633	10	0.08%	0.1%	0.1%	0.11%	-		NA	NA
HEDIS	MPT: Intensive Outpatient/Partial Hospitalization Ages 0 - 12 years - Total Rate	297,934	25	0.10%	0.1%	0.1%	0.18%	-		NA	NA
HEDIS	MPT: Intensive Outpatient/Partial Hospitalization Ages 13 - 17 years - Male	64,215	21	0.39%	0.3%	0.4%	0.55%	-		NA	NA
HEDIS	MPT: Intensive Outpatient/Partial Hospitalization Ages 13 - 17 years - Female	63,725	37	0.70%	0.6%	0.8%	1.20%	-		NA	NA
HEDIS	MPT: Intensive Outpatient/Partial Hospitalization Ages 13 - 17 years - Total Rate	127,940	58	0.54%	0.5%	0.6%	0.87%	-		NA	NA
HEDIS	MPT: Outpatient Ages 0 - 12 years - Male	150,301	1,303	10.40%	10.2%	10.6%	10.47%	-		NA	NA
HEDIS	MPT: Outpatient Ages 0 - 12 years - Female	147,633	936	7.61%	7.5%	7.7%	7.03%	-		NA	NA
HEDIS	MPT: Outpatient Ages 0 - 12 years - Total Rate	297,934	2,239	9.02%	8.9%	9.1%	8.77%	-		NA	NA
HEDIS	MPT: Outpatient Ages 13 - 17 years - Male	64,215	718	13.42%	13.2%	13.7%	13.03%	-		NA	NA
HEDIS	MPT: Outpatient Ages 13 - 17 years - Female	63,725	1,179	22.20%	21.9%	22.5%	20.17%	-		NA	NA
HEDIS	MPT: Outpatient Ages 13 - 17 years - Total Rate	127,940	1,897	17.79%	17.6%	18.0%	16.61%	-		NA	NA
HEDIS	MPT: ED Ages 0 - 12 years - Male	150,301	1	0.01%	0.0%	0.0%	0.00%	n.s.		NA	NA
HEDIS	MPT: ED Ages 0 - 12 years - Female	147,633	2	0.02%	0.0%	0.0%	0.01%	-		NA	NA
HEDIS	MPT: ED Ages 0 - 12 years - Total Rate	297,934	3	0.01%	0.0%	0.0%	0.00%	-		NA	NA
HEDIS	MPT: ED Ages 13 - 17 years - Male	64,215	1	0.02%	0.0%	0.0%	0.04%	-		NA	NA
HEDIS	MPT: ED Ages 13 - 17 years - Female	63,725	7	0.13%	0.1%	0.2%	0.12%	-		NA	NA
HEDIS	MPT: ED Ages 13 - 17 years - Total Rate	127,940	8	0.08%	0.1%	0.1%	0.08%	-		NA	NA
HEDIS	MPT: Telehealth Ages 0 - 12 years - Male	150,301	1	0.01%	0.0%	0.0%	0.00%	n.s.		NA	NA
HEDIS	MPT: Telehealth Ages 0 - 12 years - Female	147,633	0	0.00%	0.0%	0.0%	0.00%	NA		NA	NA
HEDIS	MPT: Telehealth Ages 0 - 12 years - Total Rate	297,934	1	0.00%	0.0%	0.0%	0.00%	n.s.		NA	NA
HEDIS	MPT: Telehealth Ages 13 - 17 years - Male	64,215	0	0.00%	0.0%	0.0%	0.00%	NA		NA	NA
HEDIS	MPT: Telehealth Ages 13 - 17 years - Female	63,725	0	0.00%	0.0%	0.0%	0.00%	NA		NA	NA
HEDIS	MPT: Telehealth Ages 13 - 17 years - Total Rate	127,940	0	0.00%	0.0%	0.0%	0.00%	NA		NA	NA
HEDIS	IAD: Any Services Ages 0 - 12 years - Male	150,301	2	0.02%	0.0%	0.0%	0.02%	-		NA	NA
HEDIS	IAD: Any Services Ages 0 - 12 years - Female	147,633	6	0.05%	0.0%	0.1%	0.03%	-		NA	NA
HEDIS	IAD: Any Services Ages 0 - 12 years - Total Rate	297,934	8	0.03%	0.0%	0.0%	0.02%	-		NA	NA
HEDIS	IAD: Any Services Ages 13 - 17 years - Male	64,215	63	1.18%	1.1%	1.3%	1.50%	-		NA	NA
HEDIS	IAD: Any Services Ages 13 - 17 years - Female	63,725	44	0.83%	0.8%	0.9%	0.85%	-		NA	NA
HEDIS	IAD: Any Services Ages 13 - 17 years - Total Rate	127,940	107	1.00%	0.9%	1.1%	1.18%	-		NA	NA
HEDIS	IAD: Inpatient Ages 0 - 12 years - Male	150,301	0	0.00%	0.0%	0.0%	0.01%	-		NA	NA
HEDIS	IAD: Inpatient Ages 0 - 12 years - Female	147,633	0	0.00%	0.0%	0.0%	0.00%	NA		NA	NA
HEDIS	IAD: Inpatient Ages 0 - 12 years - Total Rate	297,934	0	0.00%	0.0%	0.0%	0.00%	-		NA	NA
HEDIS	IAD: Inpatient Ages 13 - 17 years - Male	64,215	3	0.06%	0.0%	0.1%	0.21%	-		NA	NA
HEDIS	IAD: Inpatient Ages 13 - 17 years - Female	63,725	7	0.13%	0.1%	0.2%	0.16%	-		NA	NA
HEDIS	IAD: Inpatient Ages 13 - 17 years - Total Rate	127,940	10	0.09%	0.1%	0.1%	0.18%	-		NA	NA

Indicator		2019 (MY 2018)					Rate Comparison				
Source	Name	Denom	Num	Rate	Lower 95% Confidence Limit	Upper 95% Confidence Limit	2018 (MY2017) Rate	2019 Rate Compared to 2018	MMC	2019 Rate Compared to MMC	HEDIS 2019 percentile
HEDIS	IAD: Intensive Outpatient/Partial Hospitalization Ages 0 - 12 years - Male	150,301	0	0.00%	0.0%	0.0%	0.00%	NA		NA	NA
HEDIS	IAD: Intensive Outpatient/Partial Hospitalization Ages 0 - 12 years - Female	147,633	0	0.00%	0.0%	0.0%	0.00%	NA		NA	NA
HEDIS	IAD: Intensive Outpatient/Partial Hospitalization Ages 0 - 12 years - Total Rate	297,934	0	0.00%	0.0%	0.0%	0.00%	NA		NA	NA
HEDIS	IAD: Intensive Outpatient/Partial Hospitalization Ages 13 - 17 years - Male	64,215	4	0.07%	0.1%	0.1%	0.08%	-		NA	NA
HEDIS	IAD: Intensive Outpatient/Partial Hospitalization Ages 13 - 17 years - Female	63,725	1	0.02%	0.0%	0.0%	0.08%	-		NA	NA
HEDIS	IAD: Intensive Outpatient/Partial Hospitalization Ages 13 - 17 years - Total Rate	127,940	5	0.05%	0.0%	0.1%	0.08%	-		NA	NA
HEDIS	IAD: Outpatient Ages 0 - 12 years - Male	150,301	1	0.01%	0.0%	0.0%	0.01%	-		NA	NA
HEDIS	IAD: Outpatient Ages 0 - 12 years - Female	147,633	5	0.04%	0.0%	0.1%	0.02%	-		NA	NA
HEDIS	IAD: Outpatient Ages 0 - 12 years - Total Rate	297,934	6	0.02%	0.0%	0.0%	0.02%	-		NA	NA
HEDIS	IAD: Outpatient Ages 13 - 17 years - Male	64,215	51	0.95%	0.9%	1.0%	0.99%	-		NA	NA
HEDIS	IAD: Outpatient Ages 13 - 17 years - Female	63,725	31	0.58%	0.5%	0.6%	0.47%	-		NA	NA
HEDIS	IAD: Outpatient Ages 13 - 17 years - Total Rate	127,940	82	0.77%	0.7%	0.8%	0.73%	-		NA	NA
HEDIS	IAD: ED Ages 0 - 12 years - Male	150,301	0	0.01%	0.0%	0.0%	0.00%	NA		NA	NA
HEDIS	IAD: ED Ages 0 - 12 years - Female	147,633	1	0.01%	0.0%	0.0%	0.01%	-		NA	NA
HEDIS	IAD: ED Ages 0 - 12 years - Total Rate	297,934	1	0.01%	0.0%	0.0%	0.00%	-		NA	NA
HEDIS	IAD: ED Ages 13 - 17 years - Male	64,215	14	0.26%	0.2%	0.3%	0.27%	-		NA	NA
HEDIS	IAD: ED Ages 13 - 17 years - Female	63,725	9	0.21%	0.2%	0.2%	0.21%	-		NA	NA
HEDIS	IAD: ED Ages 13 - 17 years - Total Rate	127,940	23	0.23%	0.2%	0.3%	0.24%	-		NA	NA
HEDIS	IAD: Telehealth Ages 0 - 12 years - Male	150,301	0	0.00%	0.0%	0.0%	0.00%	NA		NA	NA
HEDIS	IAD: Telehealth Ages 0 - 12 years - Female	147,633	0	0.00%	0.0%	0.0%	0.00%	NA		NA	NA
HEDIS	IAD: Telehealth Ages 0 - 12 years - Total Rate	297,934	0	0.00%	0.0%	0.0%	0.00%	NA		NA	NA
HEDIS	IAD: Telehealth Ages 13 - 17 years - Male	64,215	0	0.00%	0.0%	0.0%	0.00%	NA		NA	NA
HEDIS	IAD: Telehealth Ages 13 - 17 years - Female	63,725	0	0.00%	0.0%	0.0%	0.00%	NA		NA	NA
HEDIS	IAD: Telehealth Ages 13 - 17 years - Total Rate	127,940	0	0.00%	0.0%	0.0%	0.00%	NA		NA	NA

## Consumer Assessment of Healthcare Providers and Systems (CAHPS®) Survey

### Satisfaction with the Experience of Care

The following tables provide the survey results of four composite questions by two specific categories for the MCO across the last three measurement years, as available. The composite questions will target the MCOs performance strengths as well as opportunities for improvement.

Indicators from the survey chosen for reporting here include those that measure satisfaction, as well as those that highlight the supplemental questions in the survey, which cover mental health.

Due to differences in the CAHPS submissions from year to year, direct comparisons of results are not always available. Questions that are not included in the most recent survey version are not presented in the tables.

### 2019 Child CAHPS® 5.0H Survey Results

**Table 3.9: CAHPS® 2019 Child Survey Results**

Satisfaction with Child's Care	2019 (MY 2018)	2019 Rate Compared to 2018	2018 (MY 2017)	2018 Rate Compared to 2017	2017 (MY 2016)	2019 MMC Weighted Average
Satisfaction with your child's current personal doctor (rating of 8 to 10)	90.84%	▼	90.88%	▼	91.34%	90.42%
Satisfaction with specialist (rating of 8 to 10)	87.50%	▲	87.16%	▼	92.23%	84.67%
Satisfaction with health plan (rating of 8 to 10) (satisfaction with child's plan)	89.19%	▼	90.93%	▲	88.69%	85.77%
Satisfaction with child's health care (rating of 8 to 10)	90.20%	▲	89.18%	▼	89.67%	88.80%
<b>Quality of Mental Health Care</b>						
Received care for child's mental health from any provider? (usually or always)	12.27%	▲	8.91%	▲	5.94%	10.29%
Easy to get needed mental health care? (usually or always)	49.35%	▲	40.26%	▼	47.92%	18.96%
Provider you would contact for mental health services? (PCP)	64.84%	▼	65.56%	▼	70.56%	67.10%
Child's overall mental or emotional health? (very good or excellent)	81.51%	▼	83.81%	▲	82.26%	81.32%

▲ ▼ = Performance compared to prior years' rate

Shaded boxes reflect rates above the 2019 CHIP Weighted Average.



## IV: 2018 Opportunities for Improvement MCO Response

### Current and Proposed Interventions

The general purpose of this section is to assess the degree to which each PH MCO has addressed the opportunities for improvement made by IPRO in the 2018 CHIP EQR Technical Reports, which were distributed April 2019. The 2019 EQR is the first to include descriptions of current and proposed interventions from each CHIP MCO that address the 2018 recommendations.

DHS requested that MCOs submit descriptions of current and proposed interventions using the Opportunities for Improvement form developed by IPRO to ensure that responses are reported consistently across the MCOs. These activities follow a longitudinal format, and are designed to capture information relating to:

- Follow-up actions that the MCO has taken through July 31, 2019 to address each recommendation;
- Future actions that are planned to address each recommendation;
- When and how future actions will be accomplished;
- The expected outcome or goals of the actions that were taken or will be taken; and
- The MCO's process(es) for monitoring the action to determine the effectiveness of the actions taken.

The documents informing the current report include the response submitted to IPRO as of September 2019, as well as any additional relevant documentation provided by UPMC.

Table 4.1 presents UPMC's responses to opportunities for improvement cited by IPRO in the 2018 CHIP EQR Technical Report, detailing current and proposed interventions.

**Table 4.1: Current and Proposed Interventions**

**Reference Number: [UPMC] 2018.01: The MCO's rate was statistically significantly below the 2018 (MY 2017) MMC weighted average for Immunizations for Adolescents – HPV.**

Follow Up Actions Taken Through 07/31/19:

**Case management intervention –Ongoing**

Telephonic pediatric case managers address age appropriate gaps and immunizations with every member contact. Case managers assist with scheduling appointments and discuss the importance of having the pediatrician direct their care in accordance with current best practice clinical guidelines.

**Community Collaborations – Ongoing**

UPMC has community collaborations with large pediatrician practices and regional family support centers for referrals to case management services to assist with preventive care.

**Pediatric Practice-based Care Management – October 2017 and ongoing**

Pediatric practice-based care managers meet families face-to-face within provider offices to provide education, support, and assistance with scheduling appointments to close gaps in care.

**Newsletter article on the Teen Screen - July 2019**

As a way to address the challenges of completing recommended vaccines and screenings for teenagers, the Provider Partner Update (PPU) article, published on the UPMC Health Plan website, promotes the adolescent "teen screen", which packages the HPV and Menactra vaccine, Chlamydia screening, PHQ9 depression screening, and yearly flu shot.

Future Actions Planned:

The above interventions listed as “ongoing” will continue.

**Provider Partner Update (PPU) Article on HPV - scheduled for August 2019**

As a way to help improve rates for the HPV vaccine and reduce the stigma surrounding this vaccine, this PPU article encourages providers to stress to parents that the HPV vaccine is to prevent cancer.

**Community collaborations.** In November 2019, the pediatric case management department is planning a meeting with the Allegheny County Family Support Centers to improve our referral process to assist with preventive care.

**Expansion of practice-based case management**

UPMC is currently actively recruiting staff for an additional practice-based care management location.

Effectiveness is monitored by:

- Ongoing monthly HEDIS surveillance reports (review of claims data) includes Immunizations for Adolescents: HPV. The measure continues to be collected and analyzed to determine performance trends and the need for additional interventions.

UPMC *for Kids'* goal is that the rate for Immunizations for Adolescents: HPV will increase.

**Reference Number: [UPMC] 2018.02: The MCO's rate was statistically significantly below the 2018 (MY 2017) MMC weighted average for Immunizations for Adolescents - Combination 2.**

Follow Up Actions Taken Through 07/31/19:

Please refer to responses to the Immunizations for Adolescents: HPV measure above.

Future Actions Planned:

Please refer to responses to the Immunizations for Adolescents: HPV measure above.

Effectiveness is monitored by:

- Ongoing monthly HEDIS surveillance reports (review of claims data) includes Immunizations for Adolescents: Combo 2. The measure continues to be collected and analyzed to determine performance trends and the need for additional interventions.

UPMC *for Kids'* goal is that the rate for Immunizations for Adolescents: Combo 2 will increase.

**Reference Number: [UPMC] 2018.03: The MCO's rate was statistically significantly below the 2018 (MY 2017) MMC weighted average for Chlamydia Screening in Women (16-20).**

Follow Up Actions Taken Through 07/31/19:

**Educational Video on website – March 2018**

A video entitled "Why Get a Chlamydia Test?" regarding the importance of screening for chlamydia is available for members in the health library on the UPMC Health Plan website.

**Process improved practice design – April 2018 and ongoing**

Offices that are prescribers of birth control are encouraging STI screens (including CHL) with the prescribing of birth control. Practices are encouraged to complete the screen at the time of prescribing of the birth control if possible or to consider ways to improve adherence to lab testing if the screen is not possible at the point of service.

**Provider newsletter article – July 2019**

An article entitled "Supporting the "teen screen" visit" was published in the July 2019 Provider Partner Update newsletter encourages primary care physicians to include a chlamydia screening in the teen screen visit for girls 16 and older, regardless of reported sexual activity.

**Pediatric Collaborative Calls – Ongoing**

UPMC Health Plan holds quarterly telephonic meetings with pediatric providers to discuss topics of interest (including improving rates of chlamydia screenings), UPMC pediatric initiatives, best practices and problem solving issues.

**Future Actions Planned:**

Since January 2019, a Chlamydia workgroup has focused on getting a better understanding of the nuances, roadblocks, existing provider interventions and opportunities. Targeted data analysis and literature reviews of CDC and Quest Lab materials have been undertaken in order to inform future interventions.

Targeted for implementation in Q1 2020 - Development and distribution of public domain awareness pieces around CHL/STI awareness with linkages back to UPMC Health Plan to support the provider/member/family where necessary. Materials selected will include messaging to the whole population, then pieces designed for under 18 and over 18 years of age.

Targeted for Q1 2020 - a Provider Newsletter article that includes information on “Universal Chlamydia Screening,” in the female population ages 16-24, as well as how offices can best contact Quest Diagnostics for screening kits and lockbox set up at their office.

Anticipated in Q2 2020/Q3 2020 - Development of a provider CE (face to face or podcast) with a focus on CHL and the impacts of this on future life planning as well as the avenues by which screening can be complete.

**Effectiveness is monitored by:**

- Ongoing monthly HEDIS surveillance reports (review of claims data) includes Chlamydia Screening for Women (16-20). The measure continues to be collected and analyzed to determine performance trends and the need for additional interventions.

UPMC *for Kids*’ goal is that the rate for Chlamydia Screening for Women (16-20) will increase.

**Reference Number: [UPMC] 2018.04: The MCO’s rate was statistically significantly below the 2018 (MY 2017) MMC weighted average for Chlamydia Screening in Women (Total).**

**Follow Up Actions Taken Through 07/31/19:**

Please refer to responses for the Chlamydia Screening in Women (16-20) measure above.

**Future Actions Planned:**

Please refer to responses for the Chlamydia Screening in Women (16-20) measure above.

**Effectiveness is monitored by:**

- Ongoing monthly HEDIS surveillance reports (review of claims data) includes Chlamydia Screening for Women (Total). The measure continues to be collected and analyzed to determine performance trends and the need for additional interventions.

UPMC *for Kids*’ goal is that the rate for Chlamydia Screening for Women (Total) will increase.

**Reference Number: [UPMC] 2018.05: The MCO’s rate was statistically significantly below the 2018 (MY 2017) MMC weighted average for Contraceptive Care for All Women (Age 15 – 20 years): Most or Moderately Effective.**

**Follow Up Actions Taken Through 07/31/19:**

**Contraceptive trainings for providers - Q1 and Q2 2019:**

UPMC sponsored 3 contraceptive training programs for several high-volume providers to increase LARC utilization and promotion of contraceptives.

**Pediatric Quality Call - April 2019**

UPMC facilitated a pediatric quality call where pediatric offices discussed best practices for introducing teens and young adults to speak with providers on topics including sexual health without parents present.

**Discussion of interconception care- July 2019 and ongoing**

UPMC Care Managers discuss interconception care and family planning to members engaged in care management/health management programs.

**Future Actions Planned:**

Interventions listed above as “ongoing” will continue.

UPMC is hiring a pediatric coordinator who will work with practices to discuss quality topics including CCW. Target Date: Q4 2019

Care Management discussions of interconception care and family planning to members engaged in care management/health management programs will expand into CY 2020.

. Effectiveness is monitored by:

- PAMP annual reports. The measure continues to be collected and analyzed to determine performance trends and the need for interventions.

UPMC *for Kids'* goal is that the rate for Contraceptive Care for All Women (Ages 15-20): Most or Moderately Effective increases through these interventions.

**Reference Number: [UPMC] 2018.06: The MCO's rate was statistically significantly below the 2018 (MY 2017) MMC weighted average for Annual Dental Visit (2-3 Yrs).**

**Follow Up Actions Taken Through 07/31/19:****One on one PHDHP support - October 2016 and ongoing**

PHDHPs provide one on one support and family oral health hygiene planning to members/family members in person or over the phone.

**Real-time phone transfers to PHDHPs – January 2019 and ongoing**

Members/Family members who call our member services department can be transferred in real time to our PHDHP team for oral health support and encouragement on following through with scheduled appointments.

**Oral health educational brochures – August 2017 and ongoing**

Educational brochures on oral health topics were created under the principles of health literacy. These materials are distributed to members/family members during face to face engagements at dental events and community events (health fairs, etc.).

**Step by step guides for brushing and flossing – February 2017 and ongoing**

This reproduction of an ADA piece is distributed at member dental events or community events (health fairs, etc.).

**Distribution of tools for preventive care - July 2018 and ongoing**

UPMC Health Plan provides toothbrushes, toothpaste, floss and/or flossers to members and their households as part of our dental events. Water bottles to encourage water between meals and reduction of sugary drinks and toothbrush timers for adequate brushing windows are also distributed.

**Dental home assignment – November 2017 and ongoing**

Members/families with no dental service history in the past 18-24 months or more are assigned to a specific dental home to make

the linkage to dental services. This assists members in establishing relationships with community dental providers and allows the dental office to participate in engaging with the member. The Dental Home initiative aims to align members with a dentist and utilize the relationship with their PCP to facilitate appointment scheduling.

**Pop-up dental events – August 2017 and ongoing**

Events are coordinated with mobile dental providers to offer an option for dental care outside of a traditional brick and mortar and is often used as a stopgap in areas where access is a challenge. This allows a member to receive care expeditiously while connecting to a community provider before the next cleaning in six months. These events also help PCPs get members seen by a dental provider quickly while they are still motivated from the clinician’s call to action while helping community providers cope with high volumes of new patient requests. Provider access in these events was increased in May 2019.

**Topical Fluoride Varnish training – August 2017 and ongoing**

Topical Fluoride Varnish training is provided for pediatricians and family practices to help make the oral health discussion profitable in practice. The curriculum and certification are from Healthy Teeth Healthy Children which is a 1-hour CE course and accreditation.

**PHDHP support to providers – January 2018 and ongoing**

- PHDHPs provide face to face engagement/single point of contact for member engagement support and resource connection (since January 2018).
- PHDHPs provide support to primary care offices to follow up on patients that have been seen for a well-visit where oral health was discussed (noted by YD modifier on claims) or real-time data sharing (since January 2019).

**PHDHP community support – January 2018 and ongoing**

- PHDHPs participate as oral health educators at community health events (back to school, health fairs, etc.) (since January 2018).
- PHDHPs provide oral health education in daycares/preschool settings during oral health month (February) to encourage children to form good habits through a day of hands on play (since February 2018).
- PHDHPs provide oral health perspective and support for coalitions, healthy community initiatives, local interagency coordinating counsels, etc. (since January 2019).
- PHDHPs coordinate pop-up dental clinics at community partner locations (community support center) so that members can be drawn to that location and learn about the service offerings while getting care (since January 2019).

**PHDHP support for the Health Plan – January 2018 and ongoing**

- PHDHPs provide support and assistance for Health Plan team members when they are helping a member troubleshoot a care need (since January 2018).
- A warm handoff process for oral health education between care management/member services team members and a PHDHP was established (January 2019).
- Development of shared initiative and mutual support on a system level – i.e., referring to each other’s programs, developing shared projects, promotion of community dental events via our dental provider newsletter (since January 2019.)
- Continuing education support – our PHDHP team provides two continuing education opportunities a year for RN/SW/RD care managers which speak specifically to oral health (June 2019).
- PHDHPs further the oral health literacy of our care management teams which helps increase our HEDIS scores and mitigates the effects of poor oral health on disease states (June 2019 and ongoing).

**Pediatric Collaborative Calls – Ongoing**

UPMC Health Plan holds quarterly telephonic meetings with pediatric providers to discuss topics of interest (including improving rates of dental visits), UPMC pediatric initiatives, best practices and problem-solving issues.

**Future Actions Planned:**

The above listed interventions will continue.

Future actions include the addition of a dental landing page on the UPMC Health Plan website with dental information, education, videos and announcements, targeted for implementation in the 2<sup>nd</sup> quarter 2020.

An increase in the number of dental home providers is targeted for January 2020.

The addition of more mobile dental provider groups is targeted for January 2020.

Effectiveness is monitored by:

- Ongoing monthly HEDIS surveillance reports (review of claims data) includes Annual Dental Visits (Ages 2-3 Years). The measure continues to be collected and analyzed to determine performance trends and the need for additional interventions.

UPMC *for Kids*' goal is that the rate for Annual Dental Visits (Ages 2-3 Years) will increase.

**Reference Number: [UPMC] 2018.07: The MCO's rate was statistically significantly below the 2018 (MY 2017) MMC weighted average for Annual Dental Visit (11-14 Yrs).**

Follow Up Actions Taken Through 07/31/19:

Please refer to responses for the Annual Dental Visits (Ages 2-3 Years) measure above.

Future Actions Planned:

Please refer to responses for the Annual Dental Visits (Ages 2-3 Years) measure above.

Effectiveness is monitored by:

- Ongoing monthly HEDIS surveillance reports (review of claims data) includes Annual Dental Visits (Ages 11-14 Years). The measure continues to be collected and analyzed to determine performance trends and the need for additional interventions.

UPMC *for Kids*' goal is that the rate for Annual Dental Visits (Ages 11-14 Years) will increase.

**Reference Number: [UPMC] 2018.08: The MCO's rate was statistically significantly below the 2018 (MY 2017) MMC weighted average for Annual Dental Visit (15-18 Yrs).**

Follow Up Actions Taken Through 07/31/19:

Please refer to responses for the Annual Dental Visits (Ages 2-3 Years) measure above.

Future Actions Planned:

Please refer to responses for the Annual Dental Visits (Ages 2-3 Years) measure above.

Effectiveness is monitored by:

- Ongoing monthly HEDIS surveillance reports (review of claims data) includes Annual Dental Visits (Ages 15-18 Years). The measure continues to be collected and analyzed to determine performance trends and the need for additional interventions.

UPMC *for Kids*' goal is that the rate for Annual Dental Visits (Ages 15-18 Years) will increase.

**Reference Number: [UPMC] 2018.09: The MCO's rate was statistically significantly below the 2018 (MY 2017) MMC weighted average for Annual Dental Visit (Total).**

Follow Up Actions Taken Through 07/31/19:

Please refer to responses for the Annual Dental Visits (Ages 2-3 Years) measure above.

Future Actions Planned:

Please refer to responses for the Annual Dental Visits (Ages 2-3 Years) measure above.

Effectiveness is monitored by:

- Ongoing monthly HEDIS surveillance reports (review of claims data) includes Annual Dental Visits (Total). The measure continues to be collected and analyzed to determine performance trends and the need for additional interventions.

UPMC *for Kids*' goal is that the rate for Annual Dental Visits (Total) will increase.

## V. 2019 Strengths and Opportunities for Improvement

The review of MCO's 2019 performance against structure and operations standards, performance improvement projects and performance measures identified strengths and opportunities for improvement in the quality outcomes, timeliness of, and access to services for CHIP members served by this MCO.

### Strengths

- The MCO's performance was statistically significantly above/better than the MMC weighted average in 2019 (MY 2018) on the following measures:
  - Children and Adolescents' Access to PCPs (Age 25 months-6 years)
  - Childhood Immunization Status - Hepatitis B
  - Childhood Immunization Status - Hepatitis A
  - Childhood Immunization Status - Rotavirus
  - Childhood Immunization Status - Combo 4
  - Childhood Immunization Status - Combo 5
  - Childhood Immunization Status - Combo 7
  - Childhood Immunization Status - Combo 8
  - Childhood Immunization Status - Combo 9
  - Childhood Immunization Status - Combo 10
  - Lead Screening in Children (Age 2 years)
  - Developmental Screening in the First Three Years of Life - Total
  - Developmental Screening in the First Three Years of Life - 1 year
  - Developmental Screening in the First Three Years of Life - 2 years
  - Developmental Screening in the First Three Years of Life - 3 years
  - Contraceptive Care for All Women (Age 15 – 20 years): Most or Moderately Effective
  - Dental Sealants for 6-9 Year Of Children At Elevated Caries Risk
  - Dental Sealants for 6-9 Year Of Children At Elevated Caries Risk (Dental Enhanced)
  - Annual Number of Asthma Patients with One or More Asthma-Related Emergency Room Visits (Age 2 – 19 years)
  - Asthma Medication Ratio - 5 - 11 years
  - Follow Up Care for Children Prescribed ADHD Medication - Initiation Phase
  - Follow Up After Hospitalization For Mental Illness - 7 days
  - Follow Up After Hospitalization For Mental Illness - 30 days

### Opportunities for Improvement

- The MCO's performance was statistically significantly below/worse than the MMC rate in 2019 (MY 2018) as indicated by the following measures:
  - Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents - BMI percentile (12-17 years)
  - Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents - Counseling for Nutrition (12-17 years)
  - Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents - Counseling for Physical Activity (12-17 years)
  - Chlamydia Screening in Women (16-20)
  - Chlamydia Screening in Women - Total
  - Annual Dental Visit (2-3 Yrs)
  - Annual Dental Visit (15-18 Yrs)



## **VI. Summary of Activities**

### **Structure and Operations Standards**

- UPMC was found to be fully compliant on Subparts C, D and H. Compliance review findings for ABH from RY 2019 were used to make the determinations.

### **Performance Improvement Projects**

- UPMC's Lead Screening and Developmental Screening PIP Interim Reports were both validated. The MCO received feedback and subsequent information related to these activities from IPRO and CHIP in 2019.

### **Performance Measures**

- UPMC reported all HEDIS, PA Performance Measures, and CAHPS Survey performance measures in 2019 for which the MCO had a sufficient denominator.

### **2018 Opportunities for Improvement MCO Response**

- UPMC provided a response to the opportunities for improvement issued in the 2018 annual technical report for those measures on that were identified as statistically significantly below or worse the MMC.

### **2019 Strengths and Opportunities for Improvement**

- Both strengths and opportunities for improvement have been noted for UPMC in 2019. A response will be required by the MCO for the noted opportunities for improvement in 2020.

# Appendix

Figure 1: Access to Care




Figure 2: Well Care I




Figure 3: Well Care II




Figure 4: Well Care III




Figure 5: Well Care IV




Figure 6: EPSDT/Bright Futures I




Figure 7: EPSDT/Bright Futures II




Figure 8: Dental Care for Children I




Figure 9: Dental Care for Children II




Figure 10: Respiratory Conditions




Figure 11: Behavioral Health




Figure 12: Utilization

